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1. Introduction 
 
1. 1. PARP-1, Poly(ADP-ribose) polymerase 1 
 
PARP-1, Poly(ADP-ribose) polymerase 1, is the major isoform of the poly (ADP-
ribose) polymerase family, consisting of 17 proteins in humans and 16 in mice. It is a 
constitutive nuclear and mitochondrial protein with well-recognized roles in various 
essential cellular functions, such as deoxynucleic acid (DNA) repair, signal 
transduction, different cell death pathways, and a variety of pathophysiological 
conditions including burn, sepsis, diabetes and cancer. Most of the functions mediated 
by PARP are related to oxidative stress. Activation of PARP-1 in response to oxidative 
stress catalyzes the covalent attachment of the poly (ADP-ribose) (PAR) groups on 
itself and other acceptor proteins, utilizing nicotinamide adenine dinucleotide (NAD
+)  
as a substrate. Overactivation of PARP-1 depletes intracellular NAD
+
,
 
influencing 
mitochondrial electron transport, cellular adenosine triphosphate (ATP) generation and, 
if persistent, can result in necrotic cell death. 
PARP-1 has three functionally distinct domains: the N-terminal DNA-binding domain 
(DBD) responsible for PARP-1’s interaction with DNA breaks, which are also found in 
DNA ligase III. The automodification domain (AD) contains the BRCT motif, which is 
common in DNA repair and cell-cycle proteins, constituting the major protein interface 
with various nuclear partners, and the C-terminal with the catalytic domain (CAT) 
showing common structural features with the active site of bacterial (ADP-ribosylating) 
toxins (Diphteria toxin or Pertussis toxin), notably the NAD-fold (PARP signature) 
(Langelier et al., 2008) (Figure 1). The primary structure of the enzyme is highly 
conserved in eukaryotes (human and mouse enzyme have 92% homology at the level of 
amino acid sequence) with the catalytic domain showing the highest degree of 
homology between different species; the catalytic domain contains or so-called PARP 
signature is a 50-amino acid-containing block showing 100% homology between 
vertebrates. 
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Figure 1. Domain organization of the human PARP-1 (Langelier et al., 2008). PARP-1 
composed of 3 main domains, DNA-binding (DBD, residues 1-374), Modification (AD, 
residues 375-525) and Catalytic (CAT, residues 526-1014) domains. DBD contains 
three Zn-fingers (Zn1, Zn2 and Zn3), a nuclear localization signal (NLS) and a caspase 
cleavage site (C3). Modification domain has the BRCT fold (BRCA1 C terminus) with 
auto-modification property. Catalytic domain has the conserved PARP signature 
responsible for NAD
+
 binding.. 
 
1. 2.  Other PARPs 
 
Based on the comparative analysis of their catalytic domain homology, 17 mammalian 
proteins were named PARPs (Ame et al, 2004), although the nomenclature has been 
changing in recent years, and new classifications arise based on structural and 
enzymatic characterization (Hottiger et al, 2010). 
Three-dimensional structures of the catalytic domain of chicken PARP-1 and mouse 
PARP-2 showed structural homology with the active site of the bacterial ADP 
ribosylating toxin from Corynebacterium diphtheria (Collier, 2001). Recently, the β−α-
loop-β−α NAD-fold (which is the most conserved region in PARP-1 orthologous, and is 
considered the PARP signature) was used to search the non-redundant protein database 
from the National Center for Biotechnology Information (NCBI) for human PARP 
homologues. Novel putative PARPs were identified, and this increased the number of 
PARP-family members to 17. 
 PARP-2 was discovered as a residual PARP activity in embryonic fibroblast derived 
from PARP-1 deficient mice (Shieh et al., 1998; Ame et al., 1999). It has a molecular 
weight of 65kDa and it contains 570 amino acids. Crystal structure is very similar to the 
PARP-1, except for differences in the vicinity of the acceptor site that reflect 
differences in terms of substrates. It is a nuclear, DNA-dependent member of the PARP 
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family and interacts with PARP-1 and shares common partners involved in Single 
Strand Brake Repair (SSBR) and Base Excision Repair (BER). PARP-2 deficient mice 
show a delay in DNA-strand breaks resealing similar to that observed in PARP-1 
deficient cells. (de Murcia et al. 2003; Schreiber, 2002). Knockout animals for both 
genes die in the early stage of embryogenesis, which shows the importance of these two 
genes. 
PARP-3 is a mono-ADP ribosylase, a core component of the centrosome located at the 
daughter centriole throughout the cell cycle (Augustin et al., 2003). Its E and F domains 
share a 61% homology with PARP-1.  It has two splice variants, 533 and 540 amino 
acid long, respectively, with a molecular weight of 67kDa. It was reported that PARP-3 
is not activated upon binding to DNA (Loseva et al., 2010). PARP-3 interacts with 
PARP-1 suggesting a link between the DNA-damage surveillance network and the 
mitotic fidelity checkpoint.  
VPARP (PARP-4), the largest of the PARP family with a molecular weight of ~200 
kDa, possesses a mono-ADP-ribosylation feature. It is a part of the Vault particles, 
which are ribonucleoprotein (RNP) complexes containing small RNAs and proteins. 
One of the Vaults proteins (identified by the molecular tool of yeast two-hybrid system) 
showed homology with the PARP family members. It also localizes in the nuclei, is 
associated with the mitotic spindle, and is able to carry out an ADP-ribosylation 
reaction (Kickhoefer et al., 1999). VPARP4
-/-
 mice show higher sensitivity to 
carcinogen-induced tumorigenesis, suggesting a possible role in drug-induced abnormal 
tissue grow (Raval-Fernandes et al., 2005). 
PARP5a or Tankyrase-1 is a 142 kDa molecular weight protein containing 1327 amino 
acids. It was named by Smith and colleagues as TRF-interacting, ankyrin-related ADP-
ribose polymerase (Smith et al., 1998). It has a nuclear origin, but also can be found in 
the cytosol and its activity is modified by mitogen-activated protein kinases (MAPK). 
Tankyrase-1 binds to TRF-1, a telomere-specific DNA binding protein, and was found 
to have PARP activity, which raises the question whether or not telomers are under the 
control of ADP-ribosylation. It was shown that is required for the polymerization of 
mitotic spindle-associated PAR localizing to mitotic spindle poles. Tankyrase-1 
ribonucleic acid interference (RNAi) in HeLa cells showed spindle defect in a PAR 
concentration dependent manner (Chang et al., 2005). 
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PARP-5a or Tankyrase-2 is a 127 kDa protein structurally similar to tankyrase-1, except 
that it misses the N-terminal HPS domain (His, Pro, Ser residues). It possesses PARP 
activity, binds to TRF-1 and IRAP, as TNK-1 shares overlapping functions (given that 
TNK-1 and TNK-2 proteins associate and share most of their protein partners) (Sbodio 
et al. 2002). Knockdown experiments for TNK-2 showed no changes in telomerase 
capping and length, but the smaller size of the animals indicate a metabolic disturbance, 
proving the enzyme role in metabolism (Hsiao et al., 2006). 
TiPARP or PARP-7 was found when analyzing the expression patterns of messenger 
RNAs (mRNAs) after 2,3,7,8-tetrachlorodibenzo-p-dioxin treatment. It contains 657 
amino acids and has a ~75kDa molecular weight, showing similarity to PARP-1 
catalytic domain with catalytic activity on histones. It is a mono-ADP-ribosylase and 
co-localized in the nucleus with AHR (aryl hydrocarbon receptor), a transcription factor 
activated by synthetic hydrocarbons and some endogenous ligands. MacPherson and 
colleagues found that TiPARP is a transcriptional repressor of AHR (MacPherson et al., 
2013). It was also found to have a role in regulating gluconeogenesis through AHR, 
ADP-ribosylating PEPCK (phosphoenolpyruvate carboxykinase) with NAD
+
 
consumption, and decreased SIRT1 activity of PGC1α (Diani-Moore et al., 2013). 
Treatment with dioxin caused lethality in TiPARP 
-/-
 mice by day 5, with increased level 
of steatosis and toxicity in liver, while TiPARP 
+/+
 mice survived the 30 day treatment 
period (Ahmed et al., 2015). 
Other members of the PARP family not yet mentioned above can be categorized as 
CCCH-type PARPs, Macro PARPs and other PARPs. The group of CCCH-type PARPs 
contains PARP-12 and -13, and the already reviewed TiPARP above. They share a 
common CCCH-like zing finger, WWE (Tryptophan: W; Glutamate: E amino acids) 
and the catalytic domain. One of the members, PARP-13, has two isoforms. The shorter 
one in terms of size, which lacks the PARP domain, was identified as a binding protein 
to viral ribonucleic acid (RNA) and called ZAP. Screening mammalian cDNA libraries 
revealed CCCH-like zing finger protein inhibiting viral replication (Gao et al., 2002). 
Later, in another study reported by the same group that analyzed the role of zinc fingers 
of PARP-13 in viral activity, the 2nd and 4th zing finger motif were shown to have 
major decreasing activity of viral infection in the cytoplasm, while the 1st and 3rd have 
minor (Guo et al., 2004). 
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Macro domain PARPs or BAL PARPs, PARP-9,-14,-15 (BAL 1, 2, 3), belong to this 
group, having a so-called macrodomain attached to their PARP domain, 2, 3, and 1 
respectively. Macrodomains are highly conserved domains throughout the animal 
kingdoms, as they can be found at the C-terminus of macro-H2A histone proteins and in 
several non-structure proteins of ssRNA viruses. They are also found in the family of 
proteins in bacteria, archaebacteria, and eukaryotes, suggesting a ubiquitous cellular 
role. They have the capability of binding PAR. PARP-9 was described using a 
differential display method from diffuse large B-cell lymphoma (DLB-CL) patients. It 
is a ~88kDa protein that is highly expressed in fatal high-risk DLB-CLs, compared to 
the cured, low-risk group. The high-risk group cells also show higher rates of migration 
capability, indicating a PARP-9 role in the disease's malignancy (Aguiar et al., 2000). 
Apoptosis inhibition is an important step in B-lymphoid oncogenesis, and elevated 
macro PARP corresponds to hostility. PARP-14 is a binding partner of Stat6, the IL-4-
induced (interleukin-4) transcription factor, and mediates protection against apoptosis in 
IL-4 treated cells (Cho et al 2009.). The signaling pathway goes through AMPK (AMP-
activated protein kinase), a cellular energy sensor, as enhancement restored the 
glycolytic activity and the survival signaling in PARP 14
-/- 
B cells (Cho et al., 2011). It 
possesses a cell motility and focal adhesion function, namely that PARP-14 has a role in 
focal adhesion turnover, and is localized at the end of actin stress fibers (Vyas et al., 
2013). 
Other PARPs include PARP-6, PARP-8, PARP-10, PARP-11, PARP-16. Their function 
is still relatively unknown. PARP-6 is a mono-ADP-ribosyl-transferase found in 
colorectal cancer specimens. It is thought to be a tumor suppressor (Tuncel et al., 2012). 
PARP-10 inhibits c-myc, a transcriptional regulator deregulated in cancers, and has a 
role in cell proliferation (Yu et al. 2005). Its activity depends on phosphorylation by 
CDK-2-cyclin E in vitro (Chou et al., 2006). It was shown to be a mono-ADP-
ribosylase and able to regulate IL-1β- and TNF-α-dependent NFκB signaling (Verheugd 
et al., 2013). It interacts with PCNA, and is responsible for DNA damage sensitivity 
(Nicolae et al. 2013). PARP-16's crystal structure was revealed by Karlberg (Karlberg et 
al., 2012) and showed auto-mono-ADP-ribosylating activity. The enzyme is required 
during endoplasmatic reticulum stress activating stress sensors, PERK and IRE1α by 
ADP-ribosylating, these sensors, and itself (Jwa M et al., 2012).  
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The domain structure of PARPs is summarized in Figure 2, representing the new 
ARTD (ADP-ribosyltransferase diphteria toxin-like) nomenclature proposed by 
Hottiger and colleagues (Hottiger et al., 2010) according to the International Union of 
Biochemistry and Molecular Biology (IUBMB). 
Based on the domain structure of the PARP family, different interactions are possible in 
different cell compartments. Moreover, PARP-1 interacts with PARP-2 or PARP-3 and 
Tankyrase 1 and 2 (Cook et al., 2002), widening the possibilities of their biological 
functions. 
 
 
 
Figure 2. Domain Architecture of Human PARPs (Barkauskaite et al., 2015). PARP1–
16 with alternative names listed on the side domain structures. ARTD, ADP-ribosyl 
transferase diphtheria type; vPARP, vault PARP; TNKS, Tankyrase; TIPARP, TCDD 
inducible PARP; BAL, B cell aggressive lymphoma; ZC3HDC1, zinc finger CCCH-
type domain containing 1; ZC3HAV1, zinc finger CCCH-type antiviral 1; ZAP, zinc 
finger antiviral protein. Structural information availability of specific domains is 
indicated by PDB code under the specific domains. The number of amino acids 
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composing the protein is indicated on the right. The following domain names were 
used: ZnF, zinc finger; BRCT, BRCA1 C-terminal; WGR, conserved Trp-Gly-Arg 
motif domain; HD, helical domain; ART, ADP-ribosyl transferase; VIT, vault protein 
inter-alpha-trypsin; vWFA, von Willebrand type A; ANK, ankyrin; SAM, sterile alpha 
motif; CCCH ZnF, CCCH type zinc finger; WWE, three conserved residues W-W-E 
motif domain; Macro, macrodomain; RRM, RNA recognition motif; UIM, ubiquitin 
interaction motif; TM, transmembrane motif. 
 
1. 3. Metabolism of poly(ADP-ribose) 
 
1. 3. 1. Poly(ADP-ribose), pADPr Synthesis 
 
Poly(ADP-ribosylation) is a covalent, reversible modification by PARPs attaching poly-
ADP-ribose on a variety of target proteins, using NAD
+
 as the substrate (Figure 3). It is 
a conserved process among metazoa.  
In 1963, historically speaking, Chambon published that there is an enzymatic activity 
responsible for the synthesis of polymers (PAR) that requires NAD
+
. Namely, it was 
shown that 
14
C-adenine-labeled ATP incorporated into an acid-insoluble fraction in a 
nuclear extract (Chambon et al., 1963). That was the pioneer work that sparked interest 
from different laboratories and outgrew a competitive field of research.  
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Figure 3. Structure of PAR (Kraus and Lis, 2003).  
 
The synthesis of PAR polymers consists ot the following steps: (a) initiation, (b) 
elongation, and (c) branching. PAR is attached to the glutamate residues of proteins on 
the position labeled 1. The covalent bonds between ADP-ribose units are made via 
glycosidic ribose-ribose 1″ → 2′ bonds at the positions labeled 1 and. The red and blue 
arrows represent the cleavage sites for PARG and ADP-ribosyl protein lyase, 
respectively. 
pADPr is a homopolymer of ADP-ribose, and is linked by glycosidic 1"-2"bonds 
reaching up to 200 units. The first step is the initiation -- attaching mono-ADP-ribose to 
acceptor proteins, including PARP-1. In the elongation step, the mono-ADP-ribose units 
are added to the chain, reaching up to 20-50 units. Further, ADP-ribosylation may occur 
by branching of the polymer showing similar structure to ribonucleic acid (RNA) or 
DNA which was proven by the fact that antibody against pADPr recognized RNA and 
DNA. 
In resting cells, the acceptor proteins are mono- or oligo--ADP-ribosylated, while in 
stress conditions, such as under nuclear genotoxic stimuli, proteins are poly-ADP-
ribosylated. The degradation also depends on the stimuli, as stressors can trigger the 
degradation in a significantly quicker manner than in resting cells. 
There are numbers of proteins as targets for PARylation, such as RNA/DNA 
polymerases, Topoisomerase II., p53, PCNA just to name a few. Adding ADP ribose 
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units to a protein changes the protein net charge, which results in modified function. 
Usually this prevents the interaction of a DNA-binding capability, or if it occurs near 
the catalytic site of an enzyme, may result activity-modifying property (D'Amours et al. 
1999). 
Looking at the PARP structure, there are elements responsible for the PARylation. The 
N-terminal DNA binding domain (DBD) contains two zinc fingers (F1, F2) that 
underlie the structural basis for DNA strand break detection. Upon a single strand break, 
both zinc fingers participate in the PARP activation, although PARP activation by 
double-stranded breaks depends upon the F1 domain closer to the N-terminus (Ikejima 
et al., 1990, Gradwohl et al., 1990, Langelier and Pascal 2013). There is a third zinc 
finger that can be found within the DBD, and is necessary for the coordination of 
interaction with the catalytic domain upon DNA binding, which forms a head-to-tail 
structure of the homodimer (Langelier et al., 2008). 
A discovery was made regarding PAR-binding proteins that revealed 20 amino acid 
motifs with basic and hydrophobic/basic residues. The proteins identified share a 
common function, as they participate in maintaining genomic stability. The proteins are 
as follows: p53, p21CIP1/WAF1, xeroderma pigmentosum group A complementing 
protein, MSH6, DNA ligase III, XRCC1, DNA polymerase ε, DNA-PKCS, Ku70, NF-
κB, inducible nitric oxide synthase, caspase-activated DNase, and telomerase (Pleschke 
et al., 2000). Another approach, MALDI-TOF MS technology (matrix-assisted laser 
desorption-ionization time-of-flight mass spectrometry) was utilized for identifying 
pADPr binding proteins, resulting in 30 nuclear proteins as well-- mostly hnRNPs 
(heterogeneous nuclear ribonucleoproteins), proteins that bind RNA in the nucleus and 
have a role in RNA maturation and translocation (Gagne et al., 2003). 
 
1. 3. 2. Poly(ADP-Ribose) Catabolism: Poly(ADP-Ribose) 
glycohydrolase and others degrades PAR 
 
Mono-and poly-ADP-ribose units can be removed by PAR-removing enzymes (Figure 
4). A prediction was made that the lifetime of the PAR polymer is less than 1 minute, 
which indicates a strictly controlled regulation of the synthesis and degradation (Virag 
and Szabo, 2002). The principal member of the enzymes is Poly(ADP-Ribose) 
 
 
15 
glycohydrolase (PARG), which was discovered in the 70s (Miwa and Sugimura, 1971; 
Miwa et al., 1974). PARG is a product of a single gene on chromosome 10. There are 
the full-length nuclear PARG-111, PARG-102 and the cytosolic PARG-99. There is a 
PARG-60 with nuclear and mitochondrial localization. PARG-55 is an alternative splice 
variant of PARG-60 localized in mitochondria (Meyer-Ficca et al., 2004 and Meyer et 
al., 2007).  
  
 
 
Figure 4. Metabolism of poly(ADP-ribose) (Hakmé et al., 2008). PARPs hydrolyse 
NAD
+
 and catalyse adding ADP-ribose units to glutamate residues of either acceptor 
proteins (heteromodification) or themselves (automodification). x, y and z labels 
represent values from 0 to >200. PARG and ARH3 can both hydrolyse PAR at shown 
positions; activators and outcomes of PAR synthesis are also noted on the right. Ade, 
adenine; ARH3, ADP-ribosyl hydrolase-3; Nam, nicotinamide; PAR, poly(ADP-
ribose); PARG, poly(ADP-ribose) glycohydrolase; PARP, poly(ADP-ribose) 
polymerase; Rib, ribose. 
 
Primarily, the degradation of poly(ADP-ribose) is carried out by PARG, and has a 
central role of the catabolism. Inactivating the gene causes lethality in early embryonic 
age mice (Koh et al., 2004). Using the lentiviral system elegantly presented by Erdelyi 
et al., it has been shown that PARG serves as an apoptosis to necrosis switch during 
severe oxidative stress. (Erdelyi et al., 2009). 
A study reported by Oka showed an alternative enzymatic activity for the degradation of 
poly(ADP-ribose), with a similar reaction to PARG by a 39kDa enzyme called 
poly(ADP-ribose) hydrolase or ARH3, which shares amino acid identity with the 
catalytic domain of PARG (Oka et al., 2006). 
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1. 4. Biological function of PARP-1 
 
1. 4. 1. Role of PARP-1 in the differentiation and gene expression 
 
Differentiation is the process by which a cell changes from one cell type to another. 
Usually it occurs when a less specialized type becomes more specialized to fulfill 
specific tasks, so they gain new functions and lose others. This strictly controlled 
process requires concerted gene activation and repression, and results in differentiation 
into specialized cells. For example, myosatellite cells or satellite cells are precursors of 
skeletal muscle cells and upon activation re-enter the cell cycle, start proliferation and 
differentiate to myotubes. Furthermore, many fully differentiated cell types such as 
lymphocytes, fibroblasts, and hepatocytes retain the ability to proliferate, such as in the 
course of immune response, wound healing, or liver regeneration, respectively. 
Experimental data show the differentiation-modifying effect of PARP, but it is 
important to note that the effect is cell-specific. Inhibition of PARP has been shown to 
interfere with the differentiation of human granulocyte-macrophage progenitor cells to 
the macrophage cells (Francis et al., 1983). Overexpression of PARP arrested MB4 cells 
and blocked all trans-retinoic acid-induced neutrophilic differentiation (Bhatia et al., 
1995). Benzamide PARP inhibitors induced melanogenesis and differentiation of 
melanoma cells (Durkacz et al., 1992). Moreover, PARP-1 has a role in angiogenesis 
(Caldini et al., 2011; Pyriochou et al., 2008) and adipocyte differentiation (Erener et al., 
2012). Also, after DNA damage, it is of primary importance to stop replications at 
certain checkpoints to allow for the repair of DNA damage. 
Co-purification techniques revealed the interaction of PARP-1 with replication factors 
such as DNA polymerase, and DNA primase, DNA helicase, DNA ligase, 
topoisomerases I and II and key components of multiprotein replication complex 
(Simbulan-Rosenthal et al., 1996; Dantzer et al., 1998; Bauer et al., 2001). 
PARP-1 has been shown to function in various aspects of the transcription process 
through a variety of mechanisms, including roles as a modulator of chromatin, a 
coregulator for DNA-binding transcription factors, and a regulator of DNA methylation. 
Chromatin is a protein–DNA complex, the structural base of information coded, that 
comprises genomic DNA, core histones (i.e., H2A, H2B, H3, and H4), linker histones 
 
 
17 
(e.g., H1), and other chromatin-associated proteins. The basic repeating units of 
chromatin are the nucleosome (i.e., 146 base pairs of DNA wrapped around a core 
histone octamer with two copies of each core histone) and the chromatosome (i.e., 
nucleosome, plus 20–40 base pairs of linker DNA and linker DNA-binding proteins, 
such as H1) (Widom, 1998; Wolffe and Guschin, 2000). One possible way PARP-1 
regulates chromatin structure and transcription is the PARylation of proteins bind to 
chromatin and the auto-PARylation of PARP-1, which affects the structure of 
chromatin. Earlier studies showed that PARP-1 promotes decondensation, and the 
PARylation of H1 was proposed as the underlying mechanism (Poirier et al., 1982). In 
2004, Kim and colleagues showed (Kim et al., 2004) that PARP-1 and H1 compete for 
binding to nucleosomes. PARP-1 depletion by RNAi increases the binding of H1 at 
many sites of the genome (Krishnakumar et al., 2008; Krishnakumar and Kraus, 2010), 
suggesting contribution to the dynamic regulation of gene expression. A considerable 
body of evidence suggests that PARP1 directly interacts with core histones (D’Amours 
et al., 1999; Pinnola et al., 2007). Histones H3 and H4 are preferential targets for 
PARP1 binding in vitro, and they control the enzymatic activity of PARP1 (Pinnola et 
al., 2007; Kotova et al., 2011). There are a number of studies showing that histone 
variants provide the physical link between PARP-1 and chromatin. H2Ax has been 
shown to be phosphorylated at the site of DNA damage, which pADPribosylated by 
genotoxic treatments. Chemical inhibition of PARP-1 triggers the accumulation of 
phosphorylated H2Ax (Bryant et al., 2005). Also, PARP-1 and H2Ax interaction, 
outside of DNA repair, was shown during rat spermatogenesis with high levels of 
pADPr (Meyer-Ficca et al., 2005). H2Az, another histone variant highly homologous to 
H2Ax, is considered as an interacting partner of PARP-1. 
Histone variant H2Av is a functional homologue of H2Ax in Drosophila, and combines 
the function of H2Ax and H2Az proteins (Leach et al., 2000 and Madigan et al., 2002). 
Effective repair of double strand breaks by homologous recombination requires 
phosphorylation of Drosophila H2Av (acetylated by Tip60), which is followed by 
chromatin remodeling involving un-phosphorylated and phosphorylated H2Av 
exchange (Kusch et al., 2004). In this model, (1) a complex of H2Av and PARP1 is 
activated by DNA break formation; (2) phosphorylation of H2Av triggers PARP1 
enzymatic activity; (3) activated PARP1 modifies H1 histone with pADPr, which 
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removes it from damaged loci; (4) the Tip60 complex remodels local chromatin, and 
facilitates entry of DNA repair complexes; and, finally, (5) Tip60 removes Ser137-
phospho-H2Av from repaired chromatin (Thomas and Tulin, 2013). 
It is known that transcription induced during steroid response or the response of stress-
activated genes, such as hsp70, is accompanied by a local loosening of the chromatin 
structure that manifests in polytene chromosomes as ‘‘puffs’’ at the site of transcription. 
After hormone treatment, infection, and heat shock stress, pADPr polymers accumulate 
at the target loci. As a result of PARP-1 action, chromatin loosens, and gene 
transcription takes place. But how is gene expression induced? What is the role of 
PARP-1 in the transcription machinery? 
The mode of action by PARP-1 is the modification of protein by: a) the covalent 
attachment of pADPr polymers; or b) non-covalent interaction. Gagne represents a 
proteome-wide identification of pADPr binding proteins, which are classified into 6 
groups: DNA repair, DNA replication, cell cycle, chromosome organization/biogenesis, 
protein synthesis, and mRNA metabolism (Gagne et al., 2008). Evidence suggests that 
certain proteins possess pADPr-binding domains, specifically a 190 amino acid module 
known as macrodomain (Karras et al., 2005) and a novel zinc finger motif (PBZ), which 
present in many DNA damage and checkpoint proteins (Ahel et al., 2008).  
Protein shuttling by PARP-1 and pADPr is also part of the process of loosening the 
chromatin structure. The process of shuttling, or pulling proteins from nucleic acid, is a 
paramount mechanical process in the dynamic, complex environment of the nucleus. 
The role PARP1 plays in numerous nuclear activities stems from this fundamental event 
by which PARP1 covalently or noncovalently modifies proteins to dissociate from 
nucleic acid. It is believed that PARP’s broad role in shuttling proteins from nucleic 
acid is proceeded by two non-mutually exclusive events: electrorepulsion between the 
highly anionic poly-ADP-ribose and DNA/RNA, and the stealing/masking of 
DNA/RNA binding domains (D’Amours et al., 1999). Electrorepulsive shuttling occurs 
based on the repulsive force of similar charges, namely that increasing 
auto(ADP)ribosylation increases the repulsion between PARP and DNA. Removing 
PAR units by PARG increases the affinity of PARP to DNA (Ferro and Olivera, 1982; 
Zahradka and Ebisuzaki, 1982).  
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1. 4. 2. Role of PARP-1 in DNA repair 
 
PARP-1 is a key mechanism in maintaining the stability and integrity of the cell DNA. 
There are constant intracellular (normal metabolism byproducts) and extracellular 
damaging sources (radiation, chemical agents, heat shock etc.), which might modulate 
the chemical status of a cell effecting its DNA. These could subsequently cause 
mutations, chromosomal aberrations, or cell death. Based on its DNA binding ability, it 
is presumed that PARP-1 is involved in DNA repair. Inhibitors led to some conclusions 
that PARP-1 is involved in the repair processes. PARP-1 inhibition sensitizes cells to 
genotoxic stimuli (Küpper et al., 1995; Ding and Smulson, 1994), although PARP 
inhibitors have limitations due to specificity. PARP knockout mice gave a better insight 
generated by the de Murcia’s laboratory. PARP -/- mice are viable and fertile with 
normal phenotype, but are highly sensitive to ionizing radiation and alkylating agents 
(de Murcia et al., 1997). 
 
1. 4. 2. 1. The base excision repair/single-strand break repair process 
(BER/SSBR) 
 
DNA single-strand break repair is a primary cellular pathway for repairing damaged 
bases or single-strand breaks. In this mechanism DNA glycosylases, AP 
(apuric/apyrimidic) endonucleases, DNA polymerases, DNA ligases (I., III.), XRCC1 
are recruited to the damaged sites, which are repaired by either short patch (one 
nucleotide) or long-patch repair mechanisms. 
Investigating wild type and PARP-1 deficient cell extracts gave insight into the 
involvement of PARP-1 in repair. PARP-1 interacted with DNA polymerase β giving a 
striking consequence. Cell extract from PARP-1 deficient cells failed in the Long Patch 
Repair and showed moderate effect in Short Patch Repair (Dantzer et al., 2000). 
Another study showed the involvement of PARP-1 in connection with aprataxin-1 in 
single strand break, a repair protein that was found to be defective in a neuro 
degenerative disorder (ataxia oculomotor aprataxin-1). The two proteins showed a 
concerted mechanism in the recruitment of the repair process in SSB (Harris et al., 
2009). Interaction of condensin, another performer of the chromatin structure with 
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PARP-1 along XRCC1 was identified as an SSB-specific response during DNA damage 
(Heale et al., 2006) (Figure 5). 
 
 
 
Figure 5. Simplified model for the recruitment of repair factors to SSB (Mortusewitz et 
al., 2007). DNA binding domain of PARP-1 detects single-strand breaks and 
poly(ADP-ribosyl)ation occurs leading to chromatin relaxation. Further poly(ADP-
ribosyl)ation at DNA lesions releases PARP-1 enabling other factors to be recruited 
such as XRCC1. 
 
1. 4. 2. 2. Double-strand breaks (DSBs) repair by HR and NHEJ  
 
Double-strand breaks (DSB) have the most serious consequences. DSB can be provoked 
by ionizing radiation, anti-cancer drugs or even by reactive oxygen/nitrogen species. 
Nature evolved two mechanisms that step in when this type of damage develops. The 
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two major mechanisms involved are homologous recombination (HR) and non-
homologous end joining (NHEJ). HR is utilized during S and G2 phase; it uses the sister 
chromatid as a template. It requires MRN complex (Mre 11-Rad50-Nbs1), Exo1, RPA, 
Rad 51, 54. NHEJ (which are referred to as "toxic" or mutagenic), can be divided into 
classical/canonical-NHEJ and alternative-NHEJ depending on the involvement of 
KU70-KU80 complex. 
HR takes place when the NHEJ pathways are suppressed; HR requires PARP-1 proved 
by a study where chicken DT40 cells lacking PARP-1 have reduced level of HR 
capability (Hochegger et al., 2006). Ataxia telangiectasia mutated (ATM) is a DNA 
damage-responding kinase induced by the DNA damage. ATM phosphorylates the 
proteins required for DNA damage response and repair, including proteins of MRN 
(Mre11/Rad50/NBS1) complex, p53, SMC1 and histone variant H2Ax upon 
homologous recombination. ATM was shown to physically interact with PARP-1 
(Haince JF et al., 2007) (Figure 6).  
NHEJ can be divided into classical-NHEJ and alternative-NHEJ, depending on the 
active participation of KU70-KU80. Mostly, C-NHEJ occurs in cells, but A-NHEJ takes 
place to a lesser degree when C-NHEJ fails or factors are not available. In the C-NHEJ, 
KU70-KU80 complex is formed after DSB, which recruits DNA-PK phosphorylating 
subsequent proteins participating in the repair. It was shown that PARylation has effect 
on the kinase activity in vitro (Ruscetti et al., 1998). XRCC4-Lig IV catalyzes the 
ligation of DNA ends. 
When C-NHEJ fails, A-NHEJ (A-EJ) takes over the repair. There is a competition 
between PARP-1 and KU proteins for the DNA. If KU is not available, PARP-1 is 
recruited and plays an active role in the A-NHEJ. KU80
-
/
-
 cells highly depend on 
PARP-activity for the repair process, proving PARP-1 has a critical role in this 
alternative mechanism. Ligation needs the presence of XRCC1-LigIII (Figure 7). 
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Figure 6. ATM- and PAR-dependent DNA break recognition (Haince et al., 2007). 
Activation of ATM and PARP-1 by the DNA strand breaks (A), then PAR 
accumulation contributes to the recruitment of ATM providing phosphorylation of 
ATM downstream targets (B). PARP inhibition changes the phosphorylation of ATM-
dependent substrates (C). 
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Figure 7. Schematic diagram of NHEJ and A-NHEJ after DSBs (Grabarz et al., 2012).  
A. The heterodimer Ku70/Ku80 contacts with the damaged DNA and recruits DNA-
PKcs and Artemis. The latter interacts with the DNA ends and prepares it for enzymatic 
ligation by the Cernunnos-XLF/XRCC4/Ligase IV complex. B. A-EJ (for Alternative 
end-joining) is always mutagenic. Damaged DNA, which is not processed by 
Ku70/Ku80, is degraded. A-EJ is independent on Xrcc4, Ligase IV, and is dependent on 
PARP-1, Ligase III.  
 
1. 4. 2. 3. PARP-1 in nucleotide excision repair (NER) 
 
The main repair mechanism in prokaryotes and eukaryotes against UV-induced DNA 
lesions and damages is the nucleotide excision repair (NER) that includes the 
production of thymine dimers (T-T) and other cyclobutane pyrimidine dimers (CPD), as 
well as 6–4 photoproducts (6-4PP). Mutations in the repair machinery members are 
associated with xeroderma pigmentosum, Cockayne syndrome and trichothiodystrophy. 
There are two classes of NER, the global genomic (GG-NER) and transcription coupled 
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(TC-NER). The role of PARP-1 in NER is not fully understood. 
Robu and colleagues showed that PARP-1 works collaboratively with DDB2 (DNA-
binding protein 2) and XPC (xeroderma pigmentosum group C) at UV-damaged lesions 
in GG-NER (Robu et al., 2013; Luijsterburg et al., 2012; Pines et al., 2012) (Figure 8). 
 
 
 
 
Figure 8. A model of DDB2- and PARP1-dependent regulation of NER (Pines et al., 
2012). UV-DDB is recruited to the UV damage site as a part of CUL4A-RBX1 
complex. This binds to the DNA and DDB1 and DDB2 that have a role in binding 
PARP-1. CUL4A-RBX and PARP-1 regulate DDB2 by ubiquitylation and PARylation. 
The PARYlation of chromatin recruits ALC1, which has a chromatin structure 
modifying effect mobilizing XPC.  
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1. 4. 3. PARP-1 in mitochondria 
 
Although the scientific field is divided regarding the presence of mitochondrial PARP-1 
(mtPARP-1) there are bodies of evidence that support this idea and the role of PARP-1 
in mitochondrial DNA repair, bioenergetics, and mitochondrial cell death signaling 
(Masmoudi et al., 1988; Du et al., 2003; Rossi et al., 2009; Brunyanszki et al., 2016). 
Depletion of PARP-1 by siRNA in A549 lung epithelial cells or using tissue from 
PARP-1 KO mice showed enhanced mitochondrial biogenesis and mitochondrial repair 
(Szczesny et al., 2014). Mitochondrial PARP-1 activation was showed during H2O2 
treatment in U939 by our laboratory. Early mitochondrial DNA damage occurred in 
response to H2O2 challenge, which was also associated with increased PARylation 
reactions within the mitochondria (Brunyanszki et al., 2014). These processes were 
blocked by β-adrenoreceptor blockade with propranolol, the drug that used among burn 
patients after severe burn injury. 
 
1. 4. 4. PARP-1 in Cell Death  
 
PARP-1 has been implicated in different modes of cell death, apoptosis and necrosis, 
parthanatos and autophagy. The first correlation between cell death and PARP-1 was 
made by Berger (Berger et al., 1983). DNA strand breaks activate PARP-1 which plays 
in the repair process. Inhibition of PARP-1 caused the repair process to be failed while 
the persistent activation of the enzyme producing excessive poly(ADP-ribose) account 
for the rapid cell death due to decreased NAD
+
 pool and ATP synthesis. In the latter, 
PARP-1 inhibition proved to be beneficial maintaining the cellular NAD
+
 and ATP 
pools. 
Cells that are no longer needed or are a threat to the organism are destroyed by a well-
regulated cell suicide process known as programmed cell death or apoptosis. Regulated 
necrosis or necroptosis as recently used (Van den Berghe et al., 2014) was accepted as 
new phenomena after showing that tumor necrosis factor alpha (TNFα) can trigger 
necrosis mediated by Receptor-Interacting Proteins (RIPs) (Galluzzi et al., 2012). An 
other form of a caspase-independent cell death is parthanatos (Wang Y et al., 2009) 
which is accompanied with PARP-1 activation, poly(ADP-ribosyl)ation and AIF 
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(apoptosis-inducing-factor) translocation including a nuclear-mitochondrial-nuclear 
communication axis. 
Apoptosis is a tightly regulated process is accompanied by cell shrinkage, chromatin 
condensation and DNA fragmentation, blebbing of cell membrane, cellular organelles 
degradation. The apoptotic process can be divided by two subgroups: a, extrinsic 
initiated by extracellular ligands and b, intrinsic activated by intracellular stressors, 
DNA damage, oncogenic factors converging on mitochondria. One of the hallmark of 
apoptosis is the generation of the cleaved PARP-1 by caspase-3 and caspase-7. These 
two caspases cleave PARP-1 for a 24 kDa N-terminal DNA-binding domain (DBD), 
which still maintain a strong DNA binding capability, and a 89 kDa C-terminal catalytic 
fragment which loses its catalytic activity upon cleavage (Tewari et al., 1995). This 
results the inactivation of PARP-1 promoting apoptosis by ensuing DNA fragmentation 
and preserving cellular energy for ATP-sensitive steps opposing the energy depletion-
induced necrosis (Kim et al., 2000; D’ Amours et al., 2001). Herceg and Wang proved 
the above observation using caspase-uncleavable version of PARP in TNF-α-treated 
PARP-1 fibroblasts leading these cells to NAD depletion and necrosis (Herceg and 
Wang 1999).  
An intensive line of research focused on whether or not poly(ADP-ribosy)lation by 
PARP-1 makes any differences in the apoptotic process. If there is PARylation 
involved, that must be taken place at the early phase of apoptosis since PARP-1 is 
cleaved at that stage and not active catalytically. Inhibition of PARP gave contradict 
results in terms of the effect on apoptosis. Inhibition of PARP also inhibited (Shiokawa 
et al., 1997), stimulated (Ray et al., 1992; Payne et al., 1998) or did not change the 
outcome of apoptosis (Watson et al., 1995) depending on cell type, stimuli, conditions 
applied.  
Studies using PARP-1 knockout mice derived cells showed that PARP-1 mostly can be 
dispensable for apoptosis. Hepatocytes, thymocytes and neurons from knock out 
animals compared to their wild-type counterpart did not show differences in the 
apoptotic process after Fas, TNFα, γ-irradiation, or dexamethasone treatment; however 
PARP-1 cleavage is still a key step in the apoptotic machinery. 
Necrosis or necroptosis as a new nomenclature was implemented based on the fact that 
it is a well-regulated process which was considered before as a passive, unregulated 
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way of dying. It is activated by different extracellular stimuli and the most obvious 
feature of the necrosis is the disintegration of the plasma membrane and cell content 
release to the extracellular space. It has been implicated in the pathology of muscular 
dystrophy, myocardial ischemia-reperfusion injury, diabetes, Alzheimer’s, Huntington’s 
and Parkinson’s disease. The most crucial members of necroptosis are Receptor-
Interacting-Proteins1 and 3 (RIPK1 and RIPK3) which are death domain-containing 
Ser/Thr kinases and activate nuclear factor kappa B (NF-kB) pathway. That can be 
inhibited by necrostatin-1 causing no effect on the apoptotic pathway (Van den Berghe 
et al., 2014).  PARP-1 overactivation-induced necrosis was implicated in several 
pathophysiological conditions. Mouse embryonic fibroblast treated with DNA-
alkylating agent N-methyl-N-nitro-N-nitrosoguanidine (MNNG) showed mitochondrial 
dysfunction, apoptosis inducing factor (AIF) -translocation and cell death in which c-
Jun N-terminal kinase (JNK) is required for the PARP-1-induced consequences. Also, 
these effect were attenuated in RIP1 and TRAF2 (Tumor necrosis factor receptor-
associated factor 2) knock out cells which are upstream of JNK which concludes the 
PARP-1 and necrosis close relation (Xu et al., 2006). High concentration of reactive 
oxygen and nitrogen species (ROS/RNS) caused overactivation of PARP-1 leading to 
necrotic cell death in thymocytes. Cells from PARP-1 deficient mice were protected 
against oxidant-induced damage. Same was true for the pharmacological intervention by 
3-aminobenzamide or 5-iodo-6-amino-1,2-benzopyrone against the oxidative stimuli 
proving the important role of PARP-1 in the necrotic death (Virag et al., 1998 a, b). In a 
research paper published by Adam’s Laboratory the question was raised whether or not 
necrosis takes place as a single pathway or different signaling systems contributes to the 
overall outcome. DNA-alkylating agents, MNNG and methyl methanesulfonate (MMS), 
rapidly activates PARP-1, while in TNF-induced necrosis this is only a late step of the 
process. Also, PARP-1 inhibitor, 3 amino-benzamide (3-AB), attenuated the effect of 
MNNG, but failed to do so in TNF-treated cells. Finally, interfering with RIP1 and Rip3 
or blocking ceramide (imipramine) generation was unable to protect necrosis through 
the PARP pathway (Sosna et al., 2013). This work proves the complexity of the necrosis 
which can not be concluded as a simplified and uncontrolled way of death (Figure 9). 
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Figure 9. Schematic diagram of necroptosis (Aredia and Scovassi 2014). TNF induces 
the association of RIP1 and RIP3 (necrostatin is inhibiting it) in which process, PARP-1 
directly can regulate necroptosis or indirectly, producing Poly(ADP-ribose). RIP: 
Receptor-Interacting Protein. 
  
Parthanatos, which refers to PAR and the Greek word of death, is a recognized cell 
death by the Nomenclature Committee of Cell Death and it classifies as a form of 
regulated necrosis (Galluzzi et al., 2012). It is a PARP-1 activation driven upon nuclear 
damage through AIF translocation from mitochondria to nucleus showing 
phosphatidylserine externalization, loss of mitochondrial membrane potential, 
chromatin condensation, shrinkage of the cell typically seen also in apoptosis, but the 
distinction of loss of cell membrane integrity, the lack of dependence on caspase 
activation and on energy with the appearance of large 50kb DNA fragments (Figure 
10). AIF is a 62kDa transmembrane flavoprotein found in the inner mitochondrial 
membrane anchoraged which is processed to a 57kDa soluble form before its release 
(Otera et al., 2005). After different stimuli with staurosporin, c-Myc, etoposide, or 
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ceramide, in Rat-1 cells induced AIF release and it was caspase independence showed 
by using caspase inhibitor Z-VAD.fmk which failed to prevent the translocation of AIF 
and the condensation of chromatin (Daugas et al., 2000). Immortalized mouse fibroblast 
showed AIF release after N-methyl-N′-nitro-N-nitrosoguanidine, a DNA-alkylating 
agent that potently activates PARP-1, exposure which was prevented by PARP-1 
inhibitors, 1,5-dihydroxyisoquinoline (DHIQ) (300 μM) and 3,4-dihydro-5-[4-(1-
piperidinyl)butoxy]-1(2H)-isoquinolinone (DPQ) (30 μM). The translocation and the 
cytotoxic effect was also abolished in PARP-1-KO fibroblasts. The broad range of 
caspase inhibitors failed to prevent the MNNG-induced cytotoxicity proving the 
caspase-independent mechanism (Yu et al., 2002). The above mentioned observation 
was proven in a cell free system where HeLa cells nuclei activated by MNNG were 
incubated with isolated brain mitochondria showed while nuclei non treated with 
MNNG did not show AIF release. The MNNG activated nuclei treated with PARG or 
phosphodiesterase markedly reduce the AIF from the mitochondria (Yu et al., 2006). 
The release of AIF from the mitochondria is promoted by Bax (Bcl-2-associated X 
protein). It contains a nuclear localization signal (NLS) which helps the translocation 
from the cytoplasm to nucleus where it forms a complex with cyclophyllin-A and H2Ax 
resulting chromatin condensation and DNA degradation (Moubarak et al., 2007; 
Delavalle et al., 2011).  
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Figure 10. Hallmark of parthanatos: AIF translocation (Aredia and Scovassi, 2014). 
AIF, synthesized in the cytosol as a precursor (pre-AIF), in its mature form is imported 
into the mitochondria. During parthanatos, AIF is converted into its soluble form tAIF 
and translocates to the nucleus where it promotes chromatin condensation and high 
molecular weight DNA degradation through the recruitment of endonucleases and 
DNases. AIF relocalization is promoted by the accumulation of polymers of ADP-
ribose synthesized by PARPs. AIF: Apoptosis Inducing Factor; tAIF: truncated AIF. 
 
Autophagy is thought to be a self-defense mechanism helping cells with the 
maintenance of energy homeostasis degrading damaged compounds. There are different 
inducers such as oxidative stress, starvation, DNA-damage. It is mainly regulated by 
Ser/Thr kinases, mTOR (mammalian Target Of Rapamycin) and AMPK (AMP-
activated Protein Kinase). They sense metabolic changes and work on the contrary. Akt 
is also plays a crucial role since it directly phosphorylates mTOR. mTOR is the negative 
regulator and active when energy sources are high or abundant keeping autophagy in an 
“off” status. AMPK is active when nutrient is scarce, during starvation (Aredia and 
Scovassi, 2014). A constant level of autophagy can be seen in neurons and malfunction 
of autophagy may associate with Alzheimer's disease-, Parkinson's disease and 
Huntington disease. During cancer cachexia (muscle mass wasting) where myostatin 
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expression increased, mTOR/Akt pathway is inhibited (Gallot et al., 2014). Duchenne 
muscular dystrophy (DMD) is a X-linked degenerative muscle disorder affects male 
infants. In the cellular level, the condition goes hand in hand with elevated ROS 
(reactive oxygen species) production, altered Ca
2+
 homeostasis and impaired autophagy. 
Mdx-Knock-out mice, a model of DMD lacking dystrophin, an important muscle 
protein, have elevated Nox2 activity and Src kinase expression which might be 
responsible for the elevated oxidant production and decreased autophagy through 
PI3K/Akt/mTOR pathway (Pal et al., 2014). On the other hand, by sport-physiological 
mean, during ultra-endurance running as an acute exercise, when energy demands are 
high, autophagy activity is increased via dephosphorylation of forkhead box O3 
(FoxO3) (Jamart et al., 2012). Chronic aerobic exercise results different outcome of the 
autophagy process depending on the type of exercise, dietary restriction, oxidant 
production or type of muscles involved (Tam BT and Siu PM, 2014). PARP-1, as 
discussed above, is activated during oxidative stress and DNA damage which depending 
on the intensity of the stimuli could also activate the autophagy machinery. Embryonic 
fibroblasts from PARP-1
+
/
+
 and PARP-1
−
/
− 
mouse (MEF) showed different delays in 
autophagic pattern after starvation, namely the number of autophagosomes were higher 
in PARP-1
+
/
+
 compared to PARP-1
−
/
−
. The same pattern was seen after induction of 
autophagy by rapamycin. Similar results were obtained by pharmacological inhibition 
and siRNA-based depletion of PARP-1 suggesting the active role of PARP-1 in 
autophagy upon starvation. ROS production following starvation was also higher in 
MEF from parp-1
+
/
+
 . The diffusion of ROS into nucleus caused DNA damage and it 
was more pronounced in the PARP-1
+
/
+ 
cells. Cells lacking PARP-1 showed reduced 
level of ATP depletion which was corresponded with the significantly less activation of 
AMPK. In PARP-1
+
/
+ 
cells mTOR was completely inhibited suggesting the commitment 
of these cells to autophagy and also that PARP-1 might control mTOR activity during 
starvation (Rodriguez-Vargas et al., 2012). Chemotherapy often induces autophagy in 
cancer cells, moreover PARP-1 inhibition potentiating chemotherapy-induced cell 
death. MEF from PARP-1
+
/
+
 and PARP-1
−
/
− 
mouse were treated with doxorubicin, a 
DNA damaging agent, inducing a rapid, direct effect on PARP activation. NAD
+ 
and 
ATP depletion was observed in PARP-1
+
/
+
 but in PARP-1
−
/
−
 without going toward 
necrotic or apoptotic pathways. Cells from PARP-1
+
/
+
  underwent doxorubicin-induced 
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autophagy as seen by electron microscopy, but this was almost absent in  PARP-1
−
/
−
 
cells. Pharmacological inhibition of PARP-1 also protected against the autophagic 
vacuole production after doxorubicin treatment. These results suggest whether or not 
cells undergo autophagy depends on the PARP-1 activation (Munoz-Gamez et al., 
2009). In a subcutaneous tumor model, PARP-1 activation is required in the TNFSF10-
induced ADP-ribosylation of high mobility group protein B1 (HMGB1) which causes 
cancer cell death. Pharmacological inhibition or knockdown of PARP-1 decreased 
autophagy for the good of apoptosis increasing the anticancer activity (Yang et al., 
2015). Starvation and hypoxia can trigger metabolic stress, ROS production, DNA 
damage and PARP-1 activation leading to autophagy as a defensive mechanism to 
counterbalance the energy needs for these cells and to avoid cell death. Inhibiting 
PARP-1 might open new ways in therapeutic applications, probably with combination 
with other drugs, to inhibit autophagy, which in this case is an escape from death, and 
reactivate apoptosis to eliminate those cells (Figure 11). 
 
 
 
Figure 11. PARP-1 modulates starvation-induced autophagy (Virag et al., 2013). After 
deprivation of nutrients, cells undergo autophagy through the activation of 
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AMPK/inhibition of mTOR, allowing the formation of the autophagosome core. Events 
upstream of AMPK involve energy depletion, ROS production and DNA damage. In 
this scenario, PARP-1 over-activation leads to ATP depletion, acting as a feedback loop 
to reactivate autophagy. This stress signal when maintained leads eventually to cell 
death through autophagy. PARP inactivation delays autophagy and favors apoptosis. In 
the absence of PARP-1 or after PARP inactivation, ROS levels decrease and ATP drop 
is reduced. As a consequence, the feedback loop reactivated by PARP-1 is cut-down, 
and apoptosis is triggered. 
 
 
 
Figure 12. Similarities and differences in apoptosis, necrosis, autophagy and 
parthanatos (Fatokun et al., 2014). While parthanatos is generally considered to be 
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separate and distinct from necrosis, some investigators consider it to be a specific case 
of regulated necrosis, just as is necroptosis. Δψm: mitochondrial transmembrane 
potential. AIF, apoptosis-inducing factor; AMBRA1, activating molecule in Beclin-1-
regulated autophagy protein 1; ATG, autophagy; BCL2, B-cell lymphoma 2; BECN1, 
Beclin-1; CrmA, cytokine response modifier A; CYPD, cyclophilin D; CYT, 
cytochrome; DAPK1, death-associated protein kinase 1; DPQ, 3,4-dihydro-5-[4-(1- 
piperidinyl)butoxyl]-1(2H)-isoquinolinone; IMS, intermembrane space; MAP1LC3, 
microtubule-associated protein 1 light chain 3; MOMP, mitochondrial outer membrane 
permeabilization; PAAN, parthanatos AIF-associated nuclease; PAR, poly (ADP-
ribose); PP2A, protein phosphatase 2A; RIP, receptor-interacting protein; SQSTM1, 
sequestosome 1; VPS, vacuolar protein sorting; Z-VAD-fmk, N-benzyloxycarbonyl-
Val-Ala-Asp-fluoromethylketone. 
 
The role of PARP-1 in different forms of cell death such as apoptosis, necrosis, 
parthanatos or autophagy was described above. It is mainly associated with DNA 
damage in some degree but it is thought to have DNA-independent function as well 
which needs more and deeper investigation.    
These 4 types of death can be distinguished based on morphological, biochemical 
phenotype or the changes to pharmacological inhibition, as outlined in Figure 12. 
 
1. 4. 5. Role of PARP-1 in pathophysiology 
 
An unbalanced cell cycle regulation, cell proliferation or DNA-repair are hallmarks of 
tumorigenesis. Deletion of one PARP-1, -2, -3 enzymes or pharmacological inhibition 
under non-stress condition does not lead to major physiological issues or subsequently 
cancer since the abundance of other repair enzymes step in for this role in the cell. But 
when they are challenged instability occurs. PARP-1
-
/
-
 mice challenged with whole 
body γ-irradiation or N-methyl-N-nitroso urea (MNU) showed genomic instability. 
Cells derived from PARP-1
-
/
-
 mice also displayed high sensitivity to MNU. (de Murcia 
et al., 1997, Rouleau et al., 2007). Other repair proteins and PARP simultaneous 
deletion led to embryonic lethality or tumor formation (De Vos et al., 2012). 
Reactive oxygen/nitrogen species (ROS/RNS) damage the cells and the components of 
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it such as proteins, lipids, nucleic acids. Generally speaking, under oxidative/nitrosative 
stimuli PARP-1 is activated and contributes to the DNA repair function. Depending on 
the severity of the oxidative stress signal, it might induce apoptosis, necrosis or 
autophagy. This is associated with a wide spectrum of diseases including 
cardiovascular, neurological, immunological and diabetic complications (for review, see 
Virag and Szabo 2002). In the last 20 years peroxynitrite received a lot of attention, 
which also activates PARP-1 and causes PARP-1 related cell injury potentiating NFκB 
activation turning on inflammatory pathways. The other side of the coin is that PARP-1 
and PARP-2 takes part of the normal development of immune cells playing role in T 
and B-cells differentiation and function in the adaptive immunity. Inhibitors of PARP-1 
improve immune-mediated diseases such as arthritis, colitis or allergy (Rosado et al., 
2013). 
PARP-1 also has a role in energy metabolism serving as a metabolic regulator. Muscles 
from PARP-1
-
/
-
 mice showed higher mitochondrial activity, in connection with SIRT-1 
(another NAD
+
 consuming enzyme), improved glucose removal and insulin sensitivity 
(Bai and Canto 2012). Long term pharmacological inhibition of PARP improves fitness 
in mice by increasing the number of mitochondrial complexes and enhancing 
mitochondrial respiratory capacity, which in terms of a pharmacological approach opens 
new possibilities for treatment for muscle dysfunction linked to mitochondrial function 
(Pirinen et al., 2012). In young exercised mice SIRT-1 deacetylates PARP-1 decreasing 
its activity. This effect is suppressed in aged mice, but was reversible with PARP-1 
inhibitor suggesting that inhibition of PARP-1 may serve a pharmacological tool in 
muscle-related pathophysiological condition such as sarcopenia or disuse-induced 
atrophy by aging (Mohamed et al., 2014).  
The importance of PARP-1 activity has been described in several other pathological 
condition such as ischemic-reperfusion where PARP-1 is an active participant of the 
neutrophil-mediated myocardial damage upon ischemia and reperfusion and genetic 
depletion or pharmacological intervention using inhibitors of the enzyme improved the 
outcome of the injury (Zingarelli et al., 1998). In a hemorrhagic shock model, PARP-1 
was activated parallel with metabolic acidosis, lactate production which was reduced by 
PARP-1 inhibitor 3-AB in the ileum and liver (Watts et al., 2001). ROS and RNS are 
the two major contributor to endothelial dysfunction in diabetes in which PARP-1 is 
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responsible for the metabolic changes, specially since ROS/RNS can cause DNA 
damage activating the enzyme. Inhibition of the process by PARP-1 inhibitor could 
reverse the endothelial dysfunction (Soriano et al., 2001). PARP-1 activity also 
mediates inflammation in mouse model of contact hypersensitivity promoting leukocyte 
migration and expression inflammatory mediators, cytokines, chemokines and MMP 
(Matrix metalloproteinase) (Bai et al., 2009). 
Targeting repair deficient tumor cells to promote their genomic instability, improving 
muscle function in aged individuals, reducing inflammatory cytokines expression and 
leukocyte migration have a common interest: PARP inhibition. Some of the inhibitors 
already have advanced to clinical trials and give hopes to fight against these 
pathological complications. 
 
1. 5. Oxidative stress, as a trigger of PARP activation 
 
As it was discussed earlier, the best characterized activator of PARP-1 is DNA-damage 
induced by free radicals. Prolonged ROS/RNS (Reactive oxygen/nitrogen species) 
production results in an excessive PARP-1 activation reducing the cell NAD
+
 and ATP 
stores, blocking apoptosis and resulting necrosis. The better understand the role of 
PARP-1, below an overview is given about the origin of reactive oxygen/nitrogen 
species. 
Reactive oxygen and nitrogen species are known to contribute to wide variety of 
diseases such as cancer, atherosclerosis, diabetes, neurodegenerative disorders, or aging. 
As a nomenclature point of view, reactive species, either ROS or RNS, are a collective 
terms and can be divided into two subgroups, free radicals and non-radicals (Table 1). 
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Table 1. Reactive oxygen and nitrogen species (Halliwell and Whiteman 2004). 
 
Free radicals Oxidants 
 
Reactive oxygen species (ROS) 
Superoxide, O2
•−
 Hydrogen peroxide, H2O2 
Hydroxyl, OH
•
 Hypobromous acid, HOBr 
Hydroperoxyl, HO2
•
 Hypochlorous acid, HOCl 
  Ozone O3 
Peroxyl, RO2
•
 Singlet oxygen (O2
1Δg) 
Alkoxyl, RO
•
 Organic peroxides, ROOH 
Carbonate, CO3
•−
 Peroxynitrite, ONOO −  
Carbon dioxide, CO2
•−
 Peroxynitrous acid, ONOOH 
Reactive nitrogen species (RNS) 
Nitric oxide, NO
•
 Nitrous acid, HNO2 
Nitrogen dioxide, NO2
•
 Nitrosyl cation, NO
+
 
  Nitroxyl anion, NO
−
 
  Dinitrogen tetroxide, N2O4 
  Dinitrogen trioxide, N2O3 
  Peroxynitrite, ONOO− 
  Peroxynitrous acid, ONOOH 
  Nitronium (nitryl) cation, NO2
+
 
  Alkyl peroxynitrites, ROONO 
  Nitryl (nitronium) chloride, NO2Cl 
 
ROS is a collective term that includes both oxygen radicals and certain non-radicals that 
are oxidizing agents and/or are easily converted into radicals (HOCl, HOBr, O3, 
ONOO
−
, 
1
O2, H2O2). In other words, all oxygen radicals are ROS, but not all ROS are 
oxygen radicals. Peroxynitrite and H2O2 are frequently erroneously described in the 
literature as free radicals, for example. RNS is also a collective term including nitric 
oxide and nitrogen dioxide radicals, as well as non-radicals such as HNO2 and N2O4. 
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‘Reactive' is not always an appropriate term: H2O2, NO
•
 and O2
•−
 react quickly with 
only a few molecules, whereas OH
•
 reacts quickly with almost everything. RO2
•
, RO
•
, 
HOCl, NO2
•
, ONOO
−
, NO2
+
 and O3 have intermediate reactivities. We can distinguish 
endogenous and exogenous source of reactive species. The endogenous sources are 
mitochondria, peroxisomes, phagolysosomes and NO producing enzymes, NO 
synthases.  
The main producers of the reactive species are mitochondria which are continuously 
working energy producing organelles in cells and are responsible for the terminal 
oxidation and oxidative phosphorylation. In its electron (e
-
) transport chain (ETC), e
-
 is 
transferred in the inner mitochondrial membrane and the proton (H
+
) gradient generated 
used for ATP synthesis. In this system, electrons can prematurely reduce oxygen in 
Complex I., II. and Complex III producing superoxide (Figure 13). 
 
 
 
Figure 13. The mitochondrial electron transport chain produces ROS (Hamanaka and 
Chandel, 2010). Mitochondrial complexes I and II use electrons donated from NADH 
and FADH2 to reduce coenzyme Q, which shuttles these electrons to complex III, where 
they are transferred to cytochrome c. Complex IV uses electrons from cytochrome c to 
reduce molecular oxygen to water. The action of complexes I, III, and IV produce a 
proton electrochemical potential gradient, the free energy of which is used by the ATP 
synthase. Complexes I, II, and III produce superoxide through the incomplete reduction 
of oxygen to superoxide. Complexes I and II produce superoxide only into the 
mitochondrial matrix. Complex III produces superoxide into both the matrix and the 
intermembrane space. 
Peroxisomes are multifunctional organelles in eukaryotic cells oxidizing fatty acids by 
the α- and β-oxidation, participating ether-phospholipid biosynthesis, amino acid 
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catabolism, polyamine oxidation. There are different peroxisomal oxidases as part of the 
metabolic pathways that produce ROS/RNS. NOS2, inducible nitric oxide synthase was 
also described in peroxisomes capable of producing ROS and RNS. Release of ROS and 
RNS can damage the peroxisome at the site of production or escaping from the 
organelle and subsequently can lead to other signaling pathways and damaging effect in 
the cells (Figure 14). 
 
 
 
Figure 14. ROS and RNS production in the peroxisome (Fransen et al., 2012). 
Peroxisomes contain various enzymes that produce hydrogen peroxide (H2O2), 
superoxide (O2
−
), or nitric oxide (NO ) as part of their normal catalytic cycle. These 
molecules can readily react to form other ROS and RNS such as peroxynitrite 
(ONOO
−
), hydroxyl radical ( OH), and alkyl peroxides (ROOH). Peroxisomes are also 
well equipped with enzymatic and non ezymatic antioxidant defense systems, including 
catalase (CAT), superoxide dismutase 1 (SOD1), peroxiredoxin 5 (PRDX5), glutathione 
S‐ transferase kappa (GSTK1), ‘microsomal’ glutathione S‐ transferase (MGST1), 
epoxide hydrolase 2 (EPHX2), reduced glutathione (GSH) and vitamin C (VitC). GSH 
and VitC most likely freely penetrate the peroxisomal membrane through PXMP2, a 
non‐ selective pore‐ forming protein with an upper molecular size limit of 300–600 Da. 
Excess peroxisomal ROS/RNS can directly inactivate peroxisomal matrix proteins or 
promote the production of potential signaling molecules such as S‐ nitrosoglutathione 
(GSNO). Alternatively, some of these small reactive molecules may induce membrane 
damage through lipid peroxidation or diffuse out of the organelle. The latter event may 
perturb the cellular redox status, a condition generally considered as a risk factor for the 
development of age‐ related diseases. Finally, under conditions of increased oxidative 
stress, peroxisomes may also function as a sink for cellular ROS. XDH, xanthine 
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oxidase; NOS2, inducible nitric oxide synthase; GRX, glutaredoxin; ROH, alcohol; 
ONO
−
, nitrite. 
 
Phagolysosomes are organelles which actually use reactive species to destroy invaders. 
It is a single-membrane phagosome fused with a lysosome. They could be found in 
certain white blood cells such as granulo-, mono- and lymphocytes (Forman and Torres 
2001).   
 
1. 5. 1. The effect of the oxidative/nitrosative stress in the context of 
PARP 
 
In general, ROS and RNS are capable of damaging polyunsaturated fatty acids, proteins, 
nucleic acids altering their function leading to dysfunction. Peroxidation of lipids can 
alter the membrane assembly causing fluidity and permeability changes. The byproduct 
is 4-hydroxy-2-nonenal (HNE) and acrolein (Niki, 2009). Proteins also undergo 
oxidation upon RNS/ROS stimuli. Tyrosine residues are altered by nitration resulting 
nitrotyrosine which goes hand in hand with tertiary structure changes and loss of 
function in enzymatic activity. The products of the oxidation are aldehydes, keto- and 
carbonyl compounds of the proteins. The amount of such molecules during lifespan is 
increased specially the last third of life (Levine and Stadtman, 2001; Grune T., 2014). 
The other very important molecule, which suffers reactive species-caused damage, is 
the DNA. In the human body tens of thousands of DNA damage take place a day, which 
corrected by specific DNA repair mechanisms such as base excision repair or nucleotide 
excision repair.  The modifications are single- and double strand DNA breaks, 
modification of nucleotide bases, loss of purines and the crosslink of DNA and proteins. 
The most common form of modification is taken place at guanine site by 
*
OH which 
yields 8-hydroxy-2-deoxyguanosine (8-OHdG) (Halliwell, 2007). Whether the repair is 
successful or not and depending on the rate of the oxidative damage, cells might survive 
or undergo apoptosis or necrosis in connection with PARP-1 activation (Virag and 
Szabo, 2002).  
We have to keep in mind that the sensitivity to oxidative stress is different between 
nuclear and mitochondrial DNA, for instance while a given concentration of oxidant 
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(glucose-oxidase treatment) give a rise of DNA damage in a concentration dependent 
manner in mitochondria, the same amount of oxidant does not generate damage in the 
nuclear genetic material (Szczesny et al, 2013). 
 
1. 5. 2. Endogenous antioxidant systems 
 
In order to eliminate or neutralize the ROS/RNS products, the living cells are endowed 
with antioxidant systems and molecules. Also it is important to note the other source of 
antioxidant, which come from nutritional sources. As shown in Figure 14, there are 
enzymes such as catalase (CAT), glutathione-peroxidase (GPX) and superoxide 
dismutase (SOD) which facilitate the detoxification of the ROS/RNS species. The SOD 
converts superoxide to hydrogen peroxide while the CAT and GPX transform hydrogen 
peroxide to water. Two type of SOD can be distinguished, Cu- and Zn-SOD (SOD1) 
which are from cytoplasmic origin, and manganese-SOD (SOD2) which is found in 
mitochondria (McCord and Fridovich, 1968, Marklund, 1990). CAT and GPX are found 
in mitochondria and cytosol.  
The non-enzymatic system includes vitamins such as Vitamin C and Vitamin E, or 
belongs to the carotenoids which originated from plants.  
Although ROS are associated with harmful effects, but it was proven also that it has a 
role in signal transduction activating transcription factors which works as indicators of 
the redox status of the cell. If the oxidant/antioxidant system are unbalanced by the 
constant oxidative damage or the impairment of repair proteins, then the damage is 
inevitable.  
In skeletal muscle upon exercise the oxygen consumption rate goes relatively high 
compared to other tissue which has one particular consequence: elevated production of 
ROS during physical activity. Therefore, it is essential that muscle develop some 
mechanism, which reduce the harmful effect of ROS. Exercised animals (long-term 
swimming animals) has an increased 8-OHdG repair capacity hereby smaller amount of 
8-OHdG compared to their sedentary control. Also the carbonylated protein level was 
smaller in the exercised group (Radak et al., 1999). This work was further extended by 
including aged animals. The chymotrypsin-like activity, 8-OHdG content is also 
changed with age. Although those protein level, which undergo oxidative modification 
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do not change by the aging, the activity of proteasome complex responsible for 
elimination such proteins are elevated in trained/aged animals. The repair capacity of 
DNA caused by the presence of 8-OHdG was increased in muscle of exercised/aged 
animals compared to sedentary aged animals which suggests the beneficial effect of 
regular exercise against the increased level of 8-OHdG and elevated level of oxidatively 
modified proteins by the increased repair function and the resistance in protein against 
the oxidative stimuli (Radak et al, 2002). The age-related changes in connection with 
the exercise also showed an adaptive mechanism in human muscle (vastus lateralis), 
namely that the acetylation of 8-oxoguanine-DNA glycosylase (OGG1), which 
responsible for the base excision repair, is independent of age but it is dependent on the 
physical status. Regular exercise moreover generates an adaptive response with a more 
profitable antioxidant apparatus in skeletal muscle of human (Radak et al., 2011). 
 
1. 6. The biology of skeletal muscle 
 
The most fundamental action in life is movement. Moving the whole body, or just part 
of it, digestion in the intestinal system as it transits nutrient, the movement of the eye, 
just to name a few are essential for life. To accomplish these complex function, nature 
evolved muscle which are a very complicated system, but share a common function: 
contraction based on the molecular mechanism of action of actin and myosin. 
The animal kingdom possesses different type of muscles but they largely can be divided 
as striated and smooth. Within the striated group there are two types: skeletal and 
cardiac. The prior is classified by two regular phenotypes: fast twitch and slow twitch. 
Both have striated appearance due to the contractile proteins. There are also significant 
structural differences, which distinguish, cardiac from skeletal muscle. The latter one 
formed by multinucleated myocytes called fibers and they are not contracted by the 
neighbor cell electrical stimuli as it is seen in cardiac tissue. Conversely, cardiac cells 
work as a syncytium and they contract by the electrical stimuli which spreads 
spontaneously to neighboring cells. The action of skeletal muscle is graded: the extent 
and strength of its contraction can be altered and the stimuli that depolarizes the fiber 
initiates a contraction or no-contraction, in other words a yes or no response. 
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1. 6. 1. Molecular machinery of the contractile force 
 
The vertebrate muscle has a striated appearance and consists of multinucleated cells. 
Within the cells there are parallel structures called myofibrils. The longitudinal section 
of the myofibril shows a well-characterized unit called sarcomere and has a repeats in 
every 2.3 μm along the fibril axis. The underlying structure was revealed by early 
pioneering work in the 50’s and 60’s and opened the model for the sliding filament 
hypothesis of muscle. Two filamentous formations was distinguished: the thick which 
mainly consists of myosin and the thin filaments which is composed of actin, 
tropomyosin and troponin complex (Figure 15). In the 1940’s Albert Szent-Györgyi 
showed that at the molecular level, the contraction is based on the interplay of myosin, 
actin and ATP and it requires Mg
2+
 (1942).  
 
 
 
 
Figure 15.  Longitudinal section of frog sartorius muscle showing the overlapping thick 
and thin filaments (Huxley HE, 2004). There is a dark A band and the light I band which 
are arranged regularly. There is a central region of the A band called the H zone is a less 
dense part of that band. The I band is divided by a dense Z line.  
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1. 6. 2. Origin of skeletal muscle 
 
Skeletal muscle originates from the mesoderm which gives rise to somite, a complex 
transient embryonic structure. A cross-talk has to be taken place between the somite and 
adjacent structure to form muscle. Transplantation and isolation experiments were done 
to prove of the communication between cells. For instance, if chick or frog embryo 
mesoderm were removed and cultured with the respective dorsal neuronal tube then 
striated muscle were formed. In this interaction it is essential that growth factors (wnt 
proteins, Sonic hedge hog) and transcription factors (MyoD, Myf5, Pax3) cooperate 
with each other (Hill and Olson, 2012). 
 
1. 6. 3. The cellular basis of myogenesis in adults 
 
In the early 1960’s Alexander Mauro made discovery for existence of additional 
proliferative cells in the skeletal muscle of the tibialis anticus of the frog (Mauro, 1961). 
These cells were also found in the limbs of mouse embryos after day 15 postcoitum 
(E15) and postnatal growth. They were called satellite cells by A. Mauro which 
responsible for maintaining and repair of damaged myofibers (Hawke and Garry, 2001). 
They usually reside between the sarcolemma and basal lamina in the muscle fiber. Upon 
stimulation (exercise, damage), activating different signaling pathways (TWEAK, NF-
κB), they proliferate/differentiate to myoblasts, the progenitor of satellite cells, fusing 
into multinucleated myofibers (Figure 16). 
 
 
 
Figure 16. Mammalian skeletal myogenesis (Enwere et al., 2014).  
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Upon muscle injury, a resident population of quiescent myogenic precursor cells, 
known as satellite cells (because they encircle muscle fibers), proliferate and 
differentiate into myoblasts. They also fuse together (primary fusion step) to create 
multinucleated myocytes or myotubes over the course of several days. Additional 
myoblasts fuse to the existing myotubes in the secondary fusion step to produce even 
larger myotubes which eventually align to form muscle fibers. This differentiation 
process is regulated by many internal and external factors. Over the course of 
myogenesis, expression of stem cell markers such as Pax7 is gradually lost, while the 
appearance of differentiation markers, such as myosin heavy chain (MyHC), muscle-
regulatory factor 4 (Mrf4), and muscle creatine kinase (MCK) gradually increases. The 
NF-κB pathways are now known to play significant roles in this differentiation process. 
Upon the loss of canonical NF-κB signaling and the activation of non-canonical (or 
alternative) NF-κB signaling, myoblasts stop dividing and start fusing to form 
multinucleated myotubes, a key event in myogenesis. 
Satellite cells are heterogeneous and they can be divided into committed cells (upon 
activation they progress to myogenic lineage) and stem cells (responsible for 
maintaining the satellite pool).  In resting conditions satellite cells remain in a reversible 
and quiescent G0 state which is regulated by cyclin-dependent kinase inhibitors (such as 
p27
Kip1
, p57
Kip2
), the negative regulator of fibroblast growth factor (Spry1) or also 
maintained by muscle specific miRNAs (microRNAs). Upon activation they re-enter the 
cell cycle a, directly or through b, an intermediate state called Galert in which they show 
a greater regenerative potential. After the activation they exit and become quiescent 
again where Spry1 is upregulated and Notch signaling has important role. The 
proliferating myoblasts also exit the cell cycle under differentiation into myocytes to 
later form myotubes which occurs after a muscle injury (Dumont et al., 2015). 
As it was described earlier one of the theory for aging is the elevated ROS causing 
impaired muscle function, regeneration and the loss of muscle mass and decline in 
strength, hallmark of sarcopenia. Satellite cells density remains relatively stable during 
the aging process, but the myofibers show a decline suggesting that the potential to 
regenerate and/or to build muscle by the satellite cell population, as well as the self-
renewal to reconstitute the muscle stem cell pool are impaired.  
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During the regeneration major metabolic changes take place and need necessity for 
mitochondrial biogenesis which results increased ROS production. Using Pitx2 and 
Pitx3 mutant which are key elements in preventing excess ROS production, showed 
impaired regeneration and early onset of differentiation supporting the idea that 
controlled elevation of ROS is essential for the differentiation process, but 
overproduction impairs the normal myoblasts to myotube switch (L'Honoré et al., 
2014). Comparing the young and aged satellite cells antioxidant capacity there are 
differences that makes the ROS accumulation higher in the latter one which goes hand 
in hand with reduced myogenic potential and capacity in aged cells (Fulle et al., 2005). 
 
1. 6. 4. Skeletal muscle cells as a model system 
 
The commonly used model for myogenesis, satellite cell function and morphology is the 
use of C2C12, primary line of murine myoblasts, isolated in the late 70’s, which easily 
differentiate to myotubes under certain condition (Yaffe and Saxel, 1977). They 
behavior is very similar of satellite cells and can be used as a model system for such. 
Technically speaking, their differentiation is taken place after the C2C12 myoblasts 
became confluent and are put in medium supplemented with low percent of horse serum 
(usually 2%) slowing down their proliferation and switching them to a differentiation 
stage. During the differentiation, when fusion occurs along in changes 
phenotype/morphology, there are markers which ensure that the differentiation has 
started, namely PCNA, proliferating cell nuclear antigen, which needed for cell 
proliferation and its expression level decreased toward myotubes. Pax7, a member of a 
paired-box family of transcription factors, is also expressed in C2C12 myoblasts but it 
is downregulated to differentiation conditions (Seale P et al., 2000). Myoblasts that 
committed to the differentiation pathway express myogenin, an early marker of the 
differentiation (Andrés and Walsh, 1996). 
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2. Aims 
 
Poly(ADP-ribose) polymerase 1 (PARP-1) is the major isoform of PARP family, a 
constitutive nuclear and mitochondrial protein with well-studied roles functioning as a 
two-edged sword: a, having various essential function in DNA repair, signal 
transduction, cell death and b, pathophysiological role, mostly due to overactivation, 
seen in cancer, diabetes or sepsis. 
In differentiating muscle, from myoblasts to myotubes, we showed a marked reduction 
of PARP-1 expression toward the differentiated myotubes. 
Since PARP-1 is activated by oxidative stimuli, such as by ROS/RNS which showed to 
increased in pathophysiological condition or even by exercise raises some questions 
whether or not: 
 
 the decreased PARP-1 in myotubes means a possible advantage for the differentiated 
cells compared to the undifferentiated myoblasts against oxidative stress 
 the mitochondrial function altered and has beneficial effect comparing undifferentiated 
and differentiated cells 
 pharmacological inhibition of PARP-1 mimic the advantage of the down-regulated 
features proving our concept 
 the inhibition of PARP could be beneficial in pathological condition such as burn in 
human (propranolol suppressed PARP-1 activation in leukocytes (Brunyanszki et al., 
2014; Olah et al., 2011) 
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3. Materials and Methods 
 
3. 1. Reagents  
 
Unless otherwise indicated, all reagents were purchased from Sigma–Aldrich (St. Louis, 
MO, USA). Fetal bovine serum (FBS), horse serum, and 0.25% trypsin-EDTA were 
purchased from Life Technologies (Carlsbad, CA, USA). 
 
3. 2. Cell culture 
 
The murine C2C12 (Catalog# ATCC® CRL-1772™) and rat L6 (Catalog#ATCC® 
CRL1458™) skeletal muscle cell lines were purchased from the American Type Culture 
Collection (ATCC, Manassas, VA, USA). Undifferentiated, proliferating C2C12 and L6 
myoblasts were cultured in DMEM (ATCC, Cat#30-2002) containing 15% and 10% 
FBS, respectively. Differentiation for both cell lines was induced by changing the 
culture medium to DMEM containing 2% horse serum (Szczesny et al., 2013). All cells 
were maintained at 37 °C, 5% CO2. In supporting experiments we also used the human 
monocyte histiocytic lymphoma cell line, U937 (ATCC® CRL-1593.2™). 
Differentiation of U937 cells was induced by incubating cells with 150 nM phorbol 12-
myristate 13-acetate (PMA) for 4 days (Stoppelli et al., 1985).  
 
3. 3. Preparation of whole-cell extracts and Western blots 
  
Whole-cell extracts were prepared using NP-40 lysis buffer (20 mM Tris–HCl, pH 8.8, 
100 mM NaCl, 1 mM EDTA, 0.5% Nonidet P-40, 12 mM Na-deoxycholate). Cell 
homogenates were incubated for 30 min on ice followed by a clean-up centrifugation at 
20,000 × g for 10 min at 4°C. Protein concentration was determined with Pierce BCA 
Protein Assay Reagent (Thermo Scientific) using bovine serum albumin as a standard. 
Proteins were separated by SDS-PAGE and transferred to a nitrocellulose (Bio-Rad) 
membrane. The membrane was blocked with StartingBlock™ Blocking Buffer (Thermo 
Scientific) for 1 h followed by incubation with primary antibody: PARP-1 (1:1,000; 
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Cell Signaling, Cat#9532), PAX7 (1:1,000; Abcam, Cat#ab34360), myogenin (1:1,000; 
Abcam, ab124800), PCNA (1:1,000; Cell Signaling, Cat#2586), Histone H3 (1:1,000; 
Cell Signaling, Cat#12648P), ATP synthase (subunit alpha) (1:1000, Life  
Technologies, Cat#459240/G0531), actin-HRP (1:5,000; Santa Cruz Biotechnology, 
Cat#sc-1616 HRP); followed by incubation with anti-mouse or anti-rabbit secondary 
antibodies (Cell Signaling). The membrane was developed with SuperSignal™ West 
Pico Chemiluminescent Substrate (Pierce) and visualized in a GeneBox Detection 
System (Syngene).  
 
3. 4. MTT viability assay 
 
The MTT assay was performed as described earlier (Gerö et al., 2013). Briefly, cells 
were incubated with MTT reagent at a final concentration of 0.5 mg/ml, for 1 h at 37 
°C. The cells were washed with PBS and the residual formazan was dissolved in 
DMSO; subsequently, absorbance was measured at 570 nm with a background 
correction at 690 nm using a Molecular Devices M2 microplate reader.  
 
3. 5. LDH cytotoxicity assay  
 
Lactate dehydrogenase (LDH) release was measured as described previously (Gerö et 
al., 2014). Briefly, 30 μl of supernatant from cultured cells was mixed with 100 μl of 
freshly prepared LDH assay reagent containing 85 mM lactic acid, 1 mM nicotinamide 
adenine dinucleotide (NAD
+
), 0.27 mM N-methylphenazonium methyl sulfate (PMS), 
0.528 mM INT, and 200 mM Tris (pH 8.2). Changes in absorbance were measured 
kinetically at 492 nm for 15 min, 37 °C, using a monochromator-based reader 
(Powerwave HT, Biotek).  
 
3. 6. Measurement of NAD
+
 levels 
 
Total cellular NAD
+ 
 
was determined using NAD
+
/NADH Cell-Based Assay Kit 
(Cayman Chemical, Ann Arbor, MI, USA) according to manufacture’s 
recommendations and as previously described (Modis et al., 2012). The amount of 
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formazan produced, which is proportional to the amount of NAD
+
 in the cell lysate, was 
measured at 450nm with SpectraMax M2 microplate reader (Molecular Devices Corp., 
Sunnyvale, CA, USA).  
 
3. 7. Annexin V-phycoerythrin (Annexin V-PE) -7-aminoactinomycin 
D (7-AAD) staining for apoptosis/necrosis detection by flow cytometry  
 
Detection of cell death was performed using PE Annexin V Apoptosis Detection Kit I 
(BD Biosciences Pharmingen, San Diego, CA) according to the manufacturer’s 
recommendations. Briefly, control and treated cells were trypsinized, washed in ice-cold 
PBS and re-suspended in 1 ml Binding Buffer. 1×105
 
cells in 500 µl were incubated 
with PE Annexin V and 7-AAD for 10 min at 25°C in the dark, and analyzed 
immediately using a Guava EasyCyte Plus Flow Cytometer (Millipore, Billerica, MA). 
CytoSoft 5.3 software was used to estimate the subpopulations of early and late 
apoptotic, as well as necrotic cells, as a percentage of the total cell count (Brunyanszki 
et al., 2014). 
 
3. 8. Bioenergetic analysis in isolated mitochondria  
 
The XF24 Extracellular Flux Analyzer (Seahorse Biosciences, North Billerica, MA) 
was used to measure mitochondrial bioenergetic function. Mitochondria were isolated 
and extracellular flux analysis was performed as previously described (Frezza et al., 
2007; Rogers et al., 2011; Modis et al., 2013). Respiration by the mitochondria 
(7.5 μg/well) was sequentially measured in a coupled state with substrate present 
(5.5mM succinate; basal respiration, State 2), followed by State 3 (phosphorylating 
respiration, in the presence of ADP and substrate), State 4 (non-phosphorylating or 
resting respiration) following conversion of ADP to ATP, and State 4o, induced with 
the addition of oligomycin. Next, maximal uncoupler-stimulated respiration (State 3u) 
was detected by the administration of the uncoupling agent FCCP. At the end of the 
experiment the Complex III inhibitor, antimycin A, was applied to completely inhibit 
mitochondrial respiration. Inclusion of rotenone with succinate in the initial condition 
(State 2) triggers the respiration to be driven only by Complex II–IV. This ‘coupling 
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assay’ examines the degree of coupling between the electron transport chain (ETC) and 
the oxidative phosphorylation (OXPHOS), and can distinguish between ETC and 
OXPHOS with respect to mitochondrial function/dysfunction. 
 
3. 9. Mitochondrial membrane potential assay  
 
Changes in mitochondrial membrane potential were monitored with TMRE Membrane 
Potential Kit from Life Technologies (Carlsbad, California, USA) according to 
manufacturer's instructions and as previously described (Modis et al., 2013). Briefly, 
myoblasts were seeded at a concentration of 1×10
4 
cells per well in 96-well plates. For 
differentiated myoblasts, after the initial 24 h incubation, the culture medium was 
replaced with differentiation media and incubated for an additional 5 days. Next, cells 
were exposed to various concentrations of H2O2 for 24h. 50 nM TMRE was added to the 
media and cells were incubated for an additional 20 min at 37°C, 5% CO2; 10 and 30 
µM FCCP were used as positive controls. Changes in fluorescence (ex549/em575) were 
monitored by monochromator-based reader (Powerwave HT, Biotek). 
  
3. 10. Fluorescence microscopy 
 
Myoblasts and myotubes were fixed with 4% paraformaldehyde in PBS at room 
temperature for 15 min, washed with PBS, and permeabilized with 0.5% Triton X-100 
in PBS for 15 min at 21ºC. After washing with PBS, coverslips were incubated first in 
0.5% Triton X-100 containing 2.5% horse serum in PBS for 30 min, and then with 
primary antibodies overnight at 4ºC. For the detection of PARP-1, an anti-PARP-1 
antibody (Genetex, Cat#GTX61031) was used followed by Alexa Fluor® 546 anti-
rabbit antibody (Life Technologies, Cat#A11035). For myogenin detection, anti-
myogenin antibody (Abcam, ab124800) was used followed by Alexa Fluor® 488 anti-
rabbit antibody (Life Technologies, Cat#A11034). Cells were washed three times with 
PBS and fluorescence was visualized using a Nikon Eclipse 80i inverted microscope 
with a Photometric CoolSNAP HQ2 camera and the NIS-Elements BR 3.10 software 
(Nikon Instruments, Melville, NY, USA).  
 
 
 
52 
3. 11. PARP-1 silencing by small-interfering RNA and bioenergetic 
analysis in PARP-1 silenced cells  
 
Cells (1×10
5 
/well) were seeded into 6-well tissue culture treated plates and cultured to 
reach approximately 50% confluence in 24h. Next, cells were transfected with 40 nM 
PARP-1 specific siRNA (cat#4390771 s62054, Applied Biosystems/Ambion, Austin, 
TX, USA) using Lipofectamine™ 2000 (Invitrogen, Carlsbad, CA, USA) according to 
manufacture’s recommendations. Scrambled siRNA (Ambion, Silencer
 
Negative 
Control#1) was used as a control. After 24h, cells were harvested and seeded onto 24-
well XF24 cell culture plates. On the following day, XF24 Extracellular Flux Analyzer 
was used to measure cellular bioenergetics as described (Modis et al., 2012). 
 
3. 12. Transient transfection of myoblasts with PARP1  
 
Myoblasts were transfected on 96-well plates with full-length mouse PARP-1 cDNA 
inserted into pCMV6-Entry vector (Myc-DDK-tagged) purchased from Origene 
Technologies (Cat#MR211449) (Rockville, USA, MD). Insert free plasmid, pCMV-
Entry was used as control (Origene, Cat#PS100001). Transfection of myoblasts was 
performed using Lipofectamine 2000 (Life Technologies), according to the 
manufacturer's instructions. Briefly, DNA (0.2 µg/well) and Lipofectamine 2000 (1 
µl/well) were separately diluted in 25 µl of Opti-MEM (Gibco). Next, DNA was added 
to the Lipofectamine 2000 reagent and the lipid/DNA mixtures were allowed to form 
complex for 5 min at room temperature. Cells were washed once with 100 ul of PBS 
and 100 μl of DMEM containing 15% FBS/well was added to each well. Next, 
lipid/DNA mixture was added and cells were incubated at 37 °C, 5% CO2. After 24 h, 
transfection medium was removed and replaced with DMEM containing 2% horse 
serum to start differentiation. To validate the expression of PARP-1, anti-DDK mouse 
monoclonal antibody (1:1,000, Origene, Cat#TA50011-100) was used. After 5 days of 
differentiation, differentiation was confirmed visually (methods as described above) and 
oxidant sensitivity of the cells was tested by exposing the cells to hydrogen peroxide 
(0.8 mM) followed by the measurement of LDH release into the culture medium 
(methods as described above). 
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3. 13. Proximity Ligation Assay (PLA)  
 
In situ protein/protein proximity/interaction studies were performed with Duolink in situ 
(Olink Bioscience, Uppsala, Sweden). Cells were fixed in slide chambers (Lab-Tek) and 
incubated with the same antibodies as for Western analysis. Images were visualized 
using a Nikon Eclipse 80i fluorescent microscope with CoolSNAP HQ camera and 
analyzed with NIS-Elements BR3.10 software. 
 
3. 14. Collection of muscle samples from children with severe burn 
injury 
 
 Children aged 0 to 17 years with more than 40% total body surface area burns that 
would require skin grafting, who arrived at our hospital within 96 hours of injury, were 
eligible. All subjects received standard burn care as previously described (Herndon et 
al., 1998). Each patient underwent wound excision and grafting with skin autografts and 
allografts within 72 hours of admission. Sequential grafting procedures were performed 
over time until the wounds were 95% healed. Enteral nutrition was started at admission 
and continued until the wounds were 95% healed. Patients were fed a commercial 
enteral formula (Vivonex T.E.N.; Sandoz Nutritional, Minneapolis, MN) through a 
nasoduodenal tube. The daily caloric intake was calculated to deliver 1500 kcal per 
square meter of body-surface area burned plus 1500 kcal per square meter of total body 
surface area. Patients remained in bed for 5 days after each excision and grafting 
procedure and then were allowed daily walks. All patients were administered 
antianxiety medication after the first week post-burn. Biopsy of the vastus lateralis 
muscle was taken at various times post-burn and pooled into three groups: Early 
(samples taken at 2–6 days post-burn; n=4), Middle (13–18 days post-burn; n=4) and 
Late (69–369 days; n=8). Biopsies from cleft-lip and cleft palate patients between 3 and 
18 years of age admitted to our hospital for reconstructive surgery were used as non-
burned normal controls (n=3). Collection and analysis of the samples occurred with the 
approval of the institutional IRB committee. Patients were randomized to receive 
propranolol or no propranolol treatment, as part of a prospective randomized clinical 
trial; samples (homogenates of skeletal muscle biopsies suitable for Western blotting 
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analysis, or frozen samples suitable for immunohistochemical analysis) that were 
collected over a period of 2 years were obtained from a tissue bank for the current 
study. All samples that contained suitable volume were analyzed; no samples were 
excluded from the analysis. Patient demographic data are shown in Table 1. Biopsies 
were snap frozen at −80°C for subsequent Western blot analysis or for 
immunohistochemical analysis. 
 
Table 2. Demographic Characteristics of the Study Groups 
 
 
3. 15. Propranolol treatment  
                                                                                        
The drug was given in a regimen as previously described (Jeschke et al., 2007), at 4 
mg/kg/day by mouth from the time of admission for a period of 10±1 months. Patients 
were closely monitored for heart rate and blood pressure. Patients did not receive any 
other anabolic or anticatabolic agent. During the in-hospital portion of the treatment, 
patients received insulin if necessary (blood glucose >210 mg/dl) to decrease blood 
glucose below 210 mg/dl, with target blood glucose of 140 to 160 mg/dl. 
Pharmacokinetic studies demonstrated that in the current patient population the 
effective plasma drug concentrations were achieved in 30 minutes, and the half-life is 
approximately 4 hours (Williams et al., 2011). Skeletal muscle biopsies from the 
propranolol-treated patients, obtained in the `Middle' and `Late' time points (6–19 days 
post-burn; n=4 and 139–289 days post-burn, n=5, respectively) were compared with the 
responses seen in the respective comparable groups of control patients (not treated with 
propranolol). 
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3. 16. Western blotting for poly(ADP-ribose) (PAR) 
 
 Muscle samples were homogenized in homogenizing buffer (50mM Tris pH 7.4, 
150mM NaCl, 1% Triton-X-100, 10mM EDTA, Protease Inhibitor Cocktail (Complete 
Mini by Roche). PAR Western blotting was performed as previously described (Tóth-
Zsámboki et al., 2006). Proteins were loaded onto 4–12% polyacrylamide gels and 
separated by electrophoresis then transferred to nitrocellulose membranes. For 
immunoblotting, membranes were blocked with 10% nonfat dried milk in Tris-buffered 
saline (TBS) for 90 min. The primary antibody (anti-PAR (poly-ADP-ribose) polyclonal 
antibody, EMD Biosciences) against PAR were applied at 1 μg/ml concentrations 
overnight at 4°C. After washing 3 times in TBS containing 0.05% Tween-20 (TBST), 
the secondary antibody (peroxidase-conjugated goat anti-rabbit) were applied at 1:2000 
dilution for 1 h. Blots were washed 3 times in TBST, once in TBS, and incubated in 
enhanced chemiluminescence reagents (Supersignal WestPico Chemiluminescent 
substrate; Pierce Biotechnology, Rockford, IL, USA). The levels of PARylated protein 
at 120 kDa (representing auto-PARylation of PARP-1) were normalized to actin. 
 
3. 17. Immunohistochemical analysis 
 
Frozen sections of 5 micron thickness were prepared from all biopsy specimens 
collected. Sections were fixed in cold 95% ethanol for 10 minutes, then immersed in 3% 
hydrogen peroxide solution for 10 minutes, and rinsed with de-ionized water. Slides 
were processed at room temperature in a Dako horizontal auto-stainer, using the biotin-
streptavidin method. Both avidin and biotin were obtained from Vector Laboratories, as 
part of the AB blocking kit, and diluted 1:5 using Dako antibody diluent. Tris buffered 
saline was used to rinse slides between each of the consecutive processing steps. The 
primary antibodies were diluted in the biotin solution, each to the concentration 
specified as follows, and applied for 1 hour. Primary antibodies used in our studies 
were: 1) PAR (Tulip mouse monoclonal, anti-human 1:10); 2) CD-31 (DAKO mouse 
monoclonal, anti-human, 1:200); 3) Von Willebrand factor (DAKO mouse monoclonal, 
anti-human, 1:200); S-100 (DAKO rabbit polyclonal, anti-human, 1:4000). 
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3. 18. PAR immunostaining procedure 
 
Sections were incubated with diluted avidin for 7 minutes, rinsed, and incubated with 
the primary antibody (PAR) biotin solution for 1 hour. Afterwards, slides were 
incubated in universal secondary antibody LSAB2 (Dako) for 15 minutes, followed by 
LSAB2 labeling agent (Dako) for 15 minutes, and then diaminobenzidine (DAB, Dako) 
for 5 minutes. Slides were rinsed in distilled water, counterstained with Harris 
Hematoxylin (Fisher Scientific) for 1 minute, rinsed in distilled water first, 0.25% 
ammonia water, and distilled water as final step. Slides were then dehydrated through 
graded series of alcohols, four changes of xylene, and finally coverslipped with 
synthetic glass and permount mounting media. 
 
3. 19. Double immunostaining procedure 
 
Double immunohistochemical staining was performed according to the following 
combinations: 1) PAR (FR) and CD-31 (DAB), 2) PAR (FR) and factor VIII-related 
antigen (DAB), 3) PAR (FR) and S-100 (DAB). Sections were incubated with diluted 
avidin for 7 minutes, rinsed, and incubated with the primary antibody (CD-31, fVIII-
related antigen, or S-100) biotin solution for 1 hour. Afterwards, slides were incubated 
with PAR antibody solution (10 microg/mL) for 1 hour, and then in universal secondary 
antibody LSAB2 (Dako) for 15 minutes, followed by LSAB2 labeling agent (Dako) for 
15 minutes, and then diaminobenzidine (DAB, Dako) for 5 minutes. At this point, slides 
were incubated with the tertiary antibody solution alkaline phosphatase streptavidin 
(1:200) for 15 minutes, and then the fast-red chromagen (Biopath Labs) was applied for 
5 minutes. Slides were finally rinsed, counterstained, dehydrated and coverslipped as 
described above. 
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3. 20. Statistical analysis  
 
Data obtained from C2C12, L6 and U937 cells are shown as means ± SEM and SD. 
One-way ANOVA was applied for statistical analysis, and Tukey’s post-hoc test was 
used for the determination of significance between individual groups. The value of 
p<0.05 was considered statistically significant. All statistical calculations were 
performed using Graphpad Prism 5 analysis software. All experiments were performed 
at least 3 times on different days. 
For the analysis of human samples, nonparametric ANOVA test was applied for 
statistical analysis and for the determination of significance, the Kruskal-Wallis post-
hoc test was used. P < 0.05 considered as significant. 
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4. Results 
 
4. 1. Myoblast differentiation is associated with downregulation of 
PARP-1 expression  
 
The C2C12 cell line is a well-defined model for skeletal muscle differentiation that 
recapitulates the in vivo process through irreversible withdrawal from the cell cycle, 
repression of proliferation-associated genes, and expression of terminally differentiated 
muscle-specific genes (Yaffe and Saxel 1977; Shen et al., 2003, Ferri et al., 2009). 
Proliferating myoblasts differ from terminally differentiated, non-proliferating 
myotubes in morphology and protein expression profiles (Figure 17A, B). To confirm 
proper differentiation, we monitored the expression of transcription factor paired-box 7 
(Pax7), proliferating cell nuclear antigen (PCNA), which is known to be inhibited 
during myoblast differentiation or repression of cellular proliferation, (Frezza et al., 
2007; Rogers et al., 2011) and myogenin, which is known to be expressed in 
differentiated myotubes (Wang and Rudnicki 2012).  Time-course Western blot analysis 
of myoblast differentiation, from day 0 through 7, is shown in Figure 17 C. These 
results confirm that the process of myoblast differentiation is accurately recapitulated, 
as shown by decreased expression of Pax7 and PCNA, and increased expression of 
myogenin. Moreover, we observed a marked decrease in PARP-1 expression in 
myotubes (Figure 17C). PARP-1 expression was ten-fold greater in myoblasts than in 
myotubes (Figure 17C). Immunocytochemical analysis showed that in myoblasts, 
PARP-1 is localized mostly in the nucleus with little cytoplasmic staining, whereas 
terminally differentiated myotubes showed a global reduction of signal intensity 
(Figure 17D). To confirm our observation that skeletal muscle cell differentiation is 
accompanied by reduction in PARP-1 expression, we performed similar Western blot 
analyses using another well-defined model of skeletal muscle differentiation, namely, 
rat-derived L6 cells (Hudson et al., 2014). The obtained data clearly indicate that 
myotubes of L6 cells have reduced expression of PARP-1 (Figure 18A). Moreover, 
differentiation of U937 cells, induced by PMA, also showed a reduction in PARP1 
expression (Figure 18B). 
In order to investigate whether PARP-1 downregulation is an effect of contact 
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inhibition, confluent myoblast culture was maintained for an additional one or two days 
while the level of PARP-1 was monitored by Western blot. As shown in Figure 19, the 
level of PARP-1 was not changed under these conditions suggesting that reduction of 
the PARP-1 level is an effect of differentiation, not contact inhibition. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17. PARP1 level is reduced in myotubes. (A) Representative phase-contrast 
microscopy images of myoblasts and myotubes showing typical morphological 
differences. (B) Immunocytochemistry of the differentiation marker, myogenin, in 
myoblasts and myotubes. DAPI was used for nuclear counterstaining. Increased 
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myogenin signal was detectable in the fully differentiated myotubes. (C) The effect of 
differentiation on protein expression of PARP-1 and the differentiation markers, PCNA, 
Pax7, and myogenin were monitored on Days 0–7 using whole cell extracts. Actin was 
used as a loading control. The relative quantity of proteins was calculated by 
densitometry and normalized to actin based on the analysis of three independent 
Western blots. * indicates p<0.05 relative to myoblasts at Day 0 (100%). (D) PARP-1 
distribution in undifferentiated myoblasts and differentiated myotubes. DAPI was used 
for nuclear counterstaining. PARP-1 signal decreased in the fully differentiated 
myotubes. 
 
 
 
Figure 18. Expression of PARP-1 is reduced in differentiated L6 and U937 cells. (A) 
Western blot analysis of PARP-1, myogenin as a differentiation marker, and actin show 
the relative quantity of PARP-1 and the differentiation of L6 myoblasts and myotubes. 
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(B) Western blot analysis of PARP-1 and actin as loading control in undifferentiated 
and differentiated U937. 
 
 
 
 
Figure 19. Lack of the contact inhibitory effect on PARP-1 expression in myoblasts. (A) 
Western blot analysis of PARP-1 in myoblasts at day 1 and 2 after reaching 100% 
confluence. Actin was used as a loading control. PARP-1 densitometric analysis was 
normalized to actin (B) or PCNA (C); values obtained in Day 1 cells were set as 100%. 
The results show no significant difference in PARP-1 protein between cells kept for 1 or 
2 days after reaching 100% confluence. 
 
4. 2. Differentiated myotubes develop resistance to oxidative stress 
 
 In order to study the effect of PARP-1 inhibition, we first determined the 
maximum non-toxic concentration of well-known PARP inhibitor, PJ34 (Jagtap et al., 
2002). For our subsequent studies, we selected 10μM as the highest, non-toxic 
concentration of PJ34 based on preliminary studies with MTT conversion and LDH 
release cell-viability assays (Figure 20).  
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Figure 20. Effect of PARP inhibitor PJ34 on cell viability. Cytotoxic effect of increased 
concentration of PJ34 has been detected by LDH release (A) and MTT conversion 
assays (B). The highest concentration of PJ34 without cytotoxic effect was 10μM. Data 
are shown as mean ± SD of 3 repeats. * shows significant difference, p<0.05, in the cell 
response to PJ34 relative to controls. Data shown in A, B were calculated as percentage 
of control cells (untreated myoblasts or myotubes, in each case set as 100%). 
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Figure 21. PARylation induced by oxidative stress is reduced in myotubes. (A) 
Representative Western blot shows a maximal amount of PAR signal at 30 minutes after 
H2O2 treatment. (B) Comparison of PAR formation of myoblasts and myotubes in 
response to exposure to 0.4 mM H2O2 in the presence or absence of PJ34 at 30 min 
post-treatment. (C) Densitometric analysis of PAR level in myoblasts and myotubes. 
One-way ANOVA was used for statistical analysis and determination of significance. * 
indicates p<0.05 relative to untreated myoblasts. 
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Consistent with our observations that PARP-1 expression is downregulated in myotubes 
as compared to myoblasts, H2O2 challenge induced a lesser degree of PARP-1 
activation in myotubes than in myoblasts, as determined by Western blot analysis of 
PAR adducts in whole-cell extracts of each cell type (Figure 21). 
Next, we compared the changes in the viability of myoblasts and myotubes exposed to 
various concentrations of H2O2 by monitoring the LDH release into the culture medium, 
measuring the capacity of the cells to convert MTT to formazan, and quantifying 
cellular NAD+ levels. As expected, increasing concentration of H2O2 caused an increase 
in LDH release (Figure 22A). 200 μM H2O2 resulted in a ~5-fold increase in LDH 
release by myoblasts but not myotubes (Figure 22A). As expected, pre-treatment with 
the PARP inhibitor, PJ34, significantly reduced H2O2-induced LDH release in 
myoblasts (Figure 22A). Similarly, we observed significant reduction of both MTT 
conversion capability and NAD+ levels in myoblasts exposed to increasing 
concentrations of H2O2, but not in myotubes (Figure 22B and 22C). Similarly, PJ34 
pretreatment attenuated the deleterious effect of H2O2 in myoblasts, with only relatively 
minor effects in myotubes (Figure 22B and 22C). The cytotoxic effects of glucose 
oxidase (GOx), an alternative oxidative stressor that generates constant, low levels of 
H2O2 in culture media, were also attenuated in PJ34-treated myoblasts in a 
concentration-dependent manner (assessed by measurement of MTT reduction, Figure 
22D). Myotubes were affected only by the highest concentration of GOx and 
experienced no beneficial effect from PJ34 pre-treatment (Figure 22D). To verify our 
observations, we performed similar sets of experiments in another type of skeletal 
muscle cell line, namely, rat L6 cells. Similar to C2C12, L6 myoblasts showed a 
distinctively higher sensitivity to oxidants— as measured by MTT conversion and LDH 
release assays— that could be partially attenuated by pre-treating with PJ34 (Figure 
22E, 22F and 22G). Myotubes were more resistant to the same concentrations of H2O2 
(Figure 22E) and GOx (Figure 22F and 22G) regardless of PJ34 pre-treatment, which 
seemed to have no beneficial effect for myotubes. 
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Figure 22. Myotubes are resistant to oxidant-induced loss of cell viability. Cell viability 
of myoblasts and myotubes in response to increasing concentration of oxidative stress 
was measured by LDH release (A, F), MTT conversion (B, D, E, G), and cellular NAD
+
 
content (C). 10μM PJ34 was used in all experiments to test the effect of PARP1 
inhibition. Experiments shown in panels A-D were performed with C2C12, and those in 
panels E-G, with L6 cells. Data represent mean ± SD. One-way ANOVA was used for 
statistical analysis and for the determination of significance between individual groups. 
*shows significant difference, p<0.05, in the cell response to H2O2 or GOx relative to 
controls while # shows significant protective effect of PJ34 in H2O2 or GOx treated 
cells, p<0.05. Data shown in A, B, C, D, E, F, and G were calculated as percentage of 
control cells (untreated myoblasts or myotubes, in each case set as 100%). 
 
Our observation that myotubes are resistant to oxidant induced stress was further 
validated by flow cytometry, which showed that oxidative stress induces cell death of 
mixed type (necrotic and apoptotic), and that PARP inhibition with PJ34 reduces cell 
death primarily by decreasing the portion of necrotic and early apoptotic cell 
populations (Figure 23A and 22B). Taken together, these data indicate that myotubes 
are more resistant to oxidative stress than myoblasts, and that the oxidative stress-
induced cell dysfunction/cell death in myoblasts involves a significant PARP-
1dependent component. 
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Figure 23. Inhibition of PARP-1 reduces subpopulations of apoptotic and necrotic cells 
induced by H2O2. C2C12 myoblasts were exposed to 0.8 mM H2O2 for 24h in the 
presence or absence of the PARP inhibitor PJ34 (10 μM). PJ34 reduced the oxidant-
induced death of the myoblasts by decreasing the proportion of the necrotic, early and 
late apoptotic cell populations. Representative dot plots (A) and analysis (B) are shown. 
One-way ANOVA was used for determining significance between groups. * shows 
significant differences, p<0.05, in the cell response to H2O2 relative to controls, while # 
shows significant protective effect of PJ34, p<0.05. Data representative of 3 different 
determinations conducted on different experimental days are shown. (Total cell number 
in each group was set to 100%). 
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4. 3. Myotubes preserve mitochondrial functions during oxidative 
stress 
 
We investigated the differences in major bioenergetics parameters in mitochondria 
isolated from C2C12 myoblasts and myotubes with Extracellular Flux Analysis (Figure 
24A). While basal respiration (State 2) did not show any significant differences between 
the two cell types, myotubes were found to have higher ATP turnover (State 3) and 
maximal respiratory capacity (State 3u) than myoblasts. (Figure 24B, 24C, 24D, 24E). 
To investigate the effect of H2O2 on mitochondrial functions of myoblasts and 
myotubes, we measured mitochondrial membrane potential. We observed a gradual 
decrease of the mitochondrial membrane potential in response to increasing 
concentration of H2O2 in the myoblasts, while the mitochondrial membrane potential 
was unaffected in the myotubes (Figure 24F). FCCP (a mitochondrial uncoupler) was 
used as a control (Figure 24F).  
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Figure 24. Cellular bioenergetics of mitochondria isolated from myoblasts and 
myotubes. Bioenergetic analysis was carried out using the Extracellular Flux Analyzer 
in response to the sequential administration of ADP (4 mM), oligomycin (2 μM), FCCP 
(4 μM), and antimycin A (4 μM) in the presence of succinate (5.5 mM) and rotenone (2 
μM). (A) Representative analysis of oxygen consumption. Calculated bioenergetics 
parameters: (B) basal respiration, (C) ATP turnover, (D) proton leak and (E) maximal 
respiratory capacity. Data are shown as means ± SD of n = 9 wells collected from n = 3 
experiments performed on 3 different days. * p<0.01, in ATP turnover and maximal 
respiratory capacity. State 2 = Basal Respiration, State 3 = ATP Turnover, State 4o = 
Proton Leak, State 3u=FCCP-stimulated Maximal Respiratory Capacity. (F) 
Mitochondrial membrane potential changes in the absence or presence of the PARP 
inhibitor PJ34 (10 μM) in C2C12 myoblasts and myotubes. Statistical analyses of n = 3 
independent experiments were assessed; where * indicates significant difference, 
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p<0.001, between control and H2O2-treated myoblasts, while # shows significant 
difference, p<0.001, between myoblasts and myotubes treated under the same 
conditions. 
 
Since PARP-1 was localized in the nucleus and in the mitochondria (Rossi et al., 2009; 
Szczesny et al., 2014) we investigated its level in both cellular fractions. As shown in 
Figure 25, reduction of PARP-1 level was found in nuclear and mitochondrial fractions 
of myoblasts as compared to myotubes (Figure 25A and 25B, respectively). 
 
 
 
Figure 25. PARP-1 protein levels in mitochondrial and nuclear fractions of myoblasts 
and myotubes. Western blot analysis detected elevated expression of PARP-1 in 
myoblasts than in myotubes for both nuclear (A) and mitochondrial (B) fractions. 
Densitometric analysis of PARP-1 protein level in myoblast was set as 100%. Statistical 
analyses of n = 3 independent experiments were assessed; where ** indicates p<0.001. 
 
We have previously shown that PARP-1 silencing significantly enhances basal 
mitochondrial bioenergetics in cultured endothelial and epithelial cells (Modis et al., 
2012). Now, we investigated the effect of transient siRNA-mediated silencing of PARP-
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1 on the bioenergetic response in C2C12 myoblasts. Silencing PARP-1 expression 
increases both oxidative phosphorylation (Figure 26A) and glycolytic activity (Figure 
26B). The latter observation is in line with recent findings showing the regulation of 
glycolytic function by PARP-1 in neurons (Andrabi et al., 2014). 
 
 
 
Figure 26. Silencing PARP-1 increases both oxidative phosphorylation and glycolytic 
activity of C2C12 myoblasts. Bioenergetic analysis of the myoblasts was conducted by 
extracellular flux analysis. In the figure, a time-course measurement of OCR (A) and 
ECAR (B) for 1Å~104 cells/well under basal conditions was followed by the sequential 
addition of oligomycin (1 μg/ml), FCCP (0.3 μM), 2-DG (5mM) and antimycin A (2 
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μg/ml). Cells with PARP-1 silencing show significantly elevated OCR values during 
basal and uncoupled respiration (*p<0.05). (C, D, E, F) Bioenergetic parameters are 
elevated in cells after siRNA silencing of PARP-1, compared to control (*p<0.01). Data 
are shown as means ± SD of n = 15 wells (each group) collected from n = 3 experiments 
performed on 3 different days. (G) Western blot analysis shows the efficiency of PARP-
1 silencing as evaluated by unpaired t-test, *p < 0.001 relative to siCTL. 
 
4. 4. Over expression of PARP1 increases the oxidant sensitivity of 
myotubes 
 
There is a possibility that, in addition to the downregulation of PARP1, a host of 
additional alterations in the transcriptome profiles between myoblasts and myotubes 
resulted in the observed phenotype of decreased oxidant sensitivity in myotubes (in 
contrast to myoblasts). Therefore, PARP1 supplementation (forced expression of 
PARP1 using a cDNA inserted into pCMV6-Entry vector) was performed in myotubes, 
followed by differentiation of the cells into myoblasts (Figure 27A). The overexpressed 
PARP-1 maintained in myotubes as detected by Western analysis using anti-DDK 
monoclonal antibody (Figure 27B). Myotubes with forced expression of PARP1 
became more sensitive to hydrogen peroxide induced cell injury: they responded with 
increased LDH release, compared to the sham-transfected myotube controls (Figure 
27C). 
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Figure 27. PARP-1 overexpression sensitizes C2C12 myotubes to oxidative stress. (A) 
PARP-1 overexpression does inhibit the differentiation of myoblasts to myotubes. (B) 
Representative western blot shows the presence of expressed, tagged PARP-1 in 
myotubes (after 5 days of differentiation from myoblasts). (C) Myotubes with 
overexpressed PARP-1 possessed increased sensitivity to oxidative stress 24 h after 0.8 
mM H2O2, as estimated by the measurement of LDH release. Data represent mean ± SD 
of n = 6 determinations. * shows significant difference, p<0.05, in the cell response to 
H2O2 relative to controls (in the absence of H2O2), while # shows a significant increase 
in LDH release in the myotubes with forced PARP-1 expression, when compared to 
control myotubes. 
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4. 5. Oxidative stress leads to an early PARP-1 activation in U937 cells 
 
10 minutes of oxidative stimulus (H2O2, 400mM) induced PARP-1 activation (auto-
PARylation of PARP-1) in the extranuclear/mitochondrial compartment, but not in the 
nucleus showed by in situ proximity ligation assay (PLA) (Figure 28).  At 3-24 hours, 
in line with other studies, nuclear PARP activation occurred. Other pathophysiologic 
steps were involved after the early-onset of PARP-1 activation such as mitochondrial 
DNA damage, cellular oxidant production and compromised cell membrane integrity. 
 
 
 
Figure 28. Auto-PARylation of PARP1 in the extranuclear and nuclear compartments 
in U937 cells during oxidative stimuli. Auto-PARylation of PARP1 was assessed by 
PAR/PARP1 in situ PLA analysis, was found extranuclearly at the early time point (10 
minutes) after H2O2 exposure, while it was localized both to the nuclear and 
extranuclear compartments by 6 hours. Representative images of at least n = 3 
independent determinations, conducted on different experimental days, are shown. 
 
4. 6. β-adrenoceptor signaling is involved in PARP-1 activation during 
H2O2 challenge 
 
Pretreatment of U937 cells with the β-receptor antagonist propranolol (10 μM) prior to 
10 minutes of H2O2 challenge significantly reduced the increase of PARylation of 
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multiple proteins and the auto-PARylation of PARP-1 (Figure 29). The regulation of 
PARP-1 activation appears to be a general phenomenon since propranolol inhibited the 
PARylation in C2C12 myoblasts during the H2O2 challenge. 
 
 
Figure 29. Propranolol regulates PARP activation in U937 and C2C12 cells during 
oxidative stress. The β-adrenoceptor antagonist propranolol (PP) decreases cellular 
PARylation in (A) U937 and C2C12 (B) cells treated with H2O2. Western blot shown 
includes three separate technical replicates (lanes) for each experimental condition. 
Densitometric analysis of PARylation in H2O2-treated cells was set as 100% and effect 
of pharmacological modulators is presented as mean ± S.E.M. of three independent 
experiments; *p<0.05. 
 
 
A 
B 
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4. 7. The positive effect of PARP inhibition in skeletal muscle biopsies 
from burn patients 
 
 
 
Figure 30. Representative PAR Western blots are shown from homogenates of skeletal 
muscle biopsies of control patients (no burn, n=3), of patients with burn injury at the 
middle stage of the disease (n=4) and of propranolol-treated patients with burn injury at 
the middle stage of the disease (n=4). The bottom part of the figure shows the 
corresponding actin loading control bands. 
 
We compared PARP activation in normal skeletal muscles and muscles from different 
time point after burn injury. We classified the burn muscle samples as 'Early'. 'Middle', 
'Late' time points based on the time range when biopsies were taken as seen in Table 1 
(Materials and Methods). 'Early' time point showed elevated PARylation while 'Middle' 
had the most pronounced PARP activation. The 'Late' time point showed a 
heterogeneous population, but still was elevated compared to healthy controls. The 
PARylation mainly affected PARP-1 at ~120kDa, although other proteins were also 
modified by the PARylation process (Figure 30). 
Immunohistochemical evaluation of PARP activation mostly was observed in the 
'Middle' group compared to control group. The signal was primarily seen in the 
capillary endothelium and co-localized with CD-31 and factor VIII-related antigen. 
Also, PAR positive staining was observed in mononuclear cells and neuroglial cells 
confirmed by S-100 staining (Figure 31). 
The other goal of the study was to evaluate the effect of propranolol therapy on the 
PARP activation. The main finding was the reduced PARylation in the 'Middle' and in 
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some degree in the 'Late' group compared to the patients who did not receive 
propranolol. (Figure 32). 
 
 
 
Figure 31. PAR localized primarily to vascular endothelial cells and mononuclear 
cells. High-power photomicrographs of frozen tissue sections studied by 
immunohistochemistry to show the activation and localization of PAR in `Middle' group 
of patients.  A: Control tissue sections, showing no significant PAR staining. Original 
magnification: 40Å~.  B: Tissue sections collected from a burn case, showing marked 
activation of PAR. Original magnification: 20Å~.  C–D: Tissue section collected from a 
burn case, showed at higher magnification, highlighting the localization of PAR-
positive staining within cells of the capillary endothelium (brown staining), while the 
nuclei of myocytes appear negative (blue counterstaining). Original magnification: (C) 
40Å~, (D) 100Å~.  E–F: Tissue sections collected from a burn case showing red 
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staining for PAR and brown staining for either CD-31 (E) or Factor VIII-related antigen 
(F), to demonstrate co-localization within vascular endothelial cells. Original 
magnification: (E, F) 100Å~. 
 
 
Figure 32. Time course of PARP activation in skeletal muscle biopsies of pediatric burn 
patients and reduction of PARP activation in skeletal muscle biopsies of pediatric burn 
patients treated with propranolol. Densitometric analysis of PAR staining, normalized 
to actin, is shown, in control subjects (no burn injury), and in the Early, Middle and 
Late stage of the disease in the absence of propranolol treatment, and the Middle and 
Late stage of the disease in the presence of propranolol treatment. Results are expressed 
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as means±SEM. *P <0.05 shows a significant increase in the PAR response, when 
compared to the control group in the `Middle' group of patients; #p<0.05 shows a 
significant inhibition of the response by propranolol in the `Middle' group of patients. 
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5. Discussion 
 
5. 1. Differentiation-associated downregulation of PARP-1 expression 
increases the resistance to oxidative stress  
 
The main conclusion of the present study is that the differentiation associated decrease 
in protein level of PARP-1 in murine skeletal muscle cells contributes to acquisition of 
marked resistance to oxidative stress and the development of a capacity to maintain 
cellular bioenergetics during oxidative challenge.  
 Cellular reprograming occurs during skeletal muscle differentiation with multiple genes 
up- and down-regulating as required to orchestrate a smooth transition from 
proliferation to cell cycle exit, then differentiation and finally, fusion of multiple cells to 
form myotubes. One of the key components of the process is the expression of muscle 
specific transcription factors, such as myogenin, which has a primary role in down-
regulating Cdk activity in order to exit the cell cycle (Zang et al., 1999). One key 
enzyme affecting chromatin remodeling and gene expression is PARP-1 (Jagtap and 
Szabo, 2005) We hypothesize that maintenance of a high level of PARP-1 expression is 
required at the earlier stages of the differentiation process in order to initiate the 
changes in the chromatin structure to facilitate reprogramming gene expression. The 
cost to the cell for this high level of PARP-1 expression is increased sensitivity to 
oxidative stress although cells do not normally experience substantial oxidative stress in 
this undifferentiated stage. 
The situation is quite different in fully differentiated myocytes. Significant oxidative 
stress is generated from normal physiological functioning of differentiated myocytes, 
e.g. skeletal muscle contraction during movement or exercise (Hepple 2014; Aoi et al. 
2014; Nikolaidis et al., 2012; Radak et al., 2002; Ji 2008; Radak 2008; Szczesny et al., 
2010). Therefore, we hypothesized that the downregulation of PARP-1 serves as a 
protective mechanism limiting the deleterious consequences of oxidant-mediated 
PARP-1 overactivation such as cellular NAD
+
  depletion, decrease in bioenergetics, or 
in extreme cases, cell death. This is particularly important for skeletal muscle, which is 
prone to oxidative damage (Sakellariou et al., 2014). 
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To investigate this hypothesis, we first determined the intracellular distribution of 
PARP-1. Our immunocytochemistry studies showed that PARP-1 is localized mainly in 
the nucleus of myoblasts, that its nuclear expression is reduced after differentiation has 
taken place in myotubes, and that this occurs parallel to an increase in extranuclear 
staining. Based on several lines of study in various cell types (Rossi et al., 2009; 
Brunyanszki et al., 2014; Szczesny et al., 2014) as well as data presented in the current 
report, this staining represents mitochondrial PARP-1. Relatively little is known about 
the functional role of mitochondrial PARP-1. Rossi and colleagues showed that the 
mitochondrial protein mitofilin co-localized with PARP-1 in the mitochondria of HeLa 
cells, thus demonstrating the mitochondrial presence of the enzyme. Using subcellular 
fractionation, we show in the current paper that myoblasts have higher levels of PARP-
1 in their mitochondria than differentiated myotubes (Figure 25B). In line with previous 
studies, the possible role of the decreased PARP-1 expression in the mitochondria of 
C2C12 might be related to the higher integrity of mtDNA in the latter cells. We have 
recently demonstrated that there are differences in mitochondrial DNA repair capability 
between myoblasts and myotubes, with myotubes having higher DNA integrity 
(Szczesny et al., 2013), and observed that low levels of oxidative stress selectively 
activate mitochondrial PARP-1 in human U937 monocytes (Brunyanszki et al., 2014, 
Figure 28). These prior findings taken together with the data presented in the current 
report suggest that both the downregulation and the intracellular distribution of PARP-1 
(from the nucleus to the mitochondria) during myoblast differentiation may contribute 
to a change in oxidative stress resistance. This is further supported by our recent 
observation that PARP-1-depletion increases the rate of the mitochondrial DNA repair 
(Szczesny et al., 2014).  
Other series of studies showed the beneficial effects of genetically disrupting and  
pharmacologically inhibiting PARP-1 in models of cerebral ischemia, oxidative and 
nitrosative stress in islet cells, myocardial post-ischemic injury, and cerebral artery 
occlusion - especially with regards to its effect on motor function (Eliasson et al., 1997; 
Heller et al., 1995; Pieper et al., 2000; Ding et al., 2001). PARP-1 was overexpressed in 
myotubes to further test whether PARP-1 downregulation is an independent contributor 
to the resistance of myotubes to oxidative stress. This intervention increased the 
oxidative stress sensitivity of the myotubes which supports the view that 
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downregulation of PARP1 during differentiation of myoblasts to myotubes directly 
regulates the oxidant-sensitivity of these cells. Nevertheless, it is obvious that a host of 
changes occur in the transcriptome profile during cell differentiation, and, therefore, 
multiple factors— in addition to PARP1 downregulation— are also likely to contribute. 
 There are a number of studies implicating PARP-1 in the regulation of cellular 
bioenergetics under normal conditions and during oxidative stress. The deletion of 
PARP-1 increases NAD
+
 content and SIRT1 activity in brown adipose tissue and 
muscle, which mimics the responses seen with SIRT1 activation (both result in 
increased energy expenditure and enhanced oxidative metabolism) (Bai et al., 2011). 
Moreover, in bEnd.3 endothelial and A549 epithelial cells, pharmacological inhibition 
and siRNA-mediated silencing of PARP-1 independently increased basal and uncoupled 
cellular respiration, suggesting that PARP-1 is a regulator of physiological 
mitochondrial function (Modis et al., 2012). Additionally, PARP-1
−/−
 muscle showed a 
marked deacetylation of PGC-1α and FOXO1, which is linked to enhanced 
mitochondrial biogenesis and a more oxidative profile of muscle fibers (Kauppinen et 
al., 2013). In line with the above-cited literature, the bioenergetic experiments 
conducted in the current study indicate that PARP-1 is a regulator of basal 
mitochondrial function and also suggest that PARP-1 regulates the glycolytic capacity 
of myoblasts — both of these functions were enhanced when PARP-1 was silenced 
(Figure 26). Based on these data, we conclude that the downregulation and 
redistribution of PARP-1 during skeletal muscle differentiation will not only create an 
oxidative stress resistance, but also enhance the cellular bioenergetics capacity of the 
differentiated muscle cell relative to the myoblast, for instance, by consuming less 
NAD
+
. Since cellular NAD
+
 levels are compartmentalized and regulated by multiple 
enzymes (Koch-Nolte et al., 2011; Dölle et al., 2013); therefore it is conceivable that 
differentiation-associated changes in the expression or activity of various enzyme 
systems that handle NAD
+
, other than PARP-1 may have also contributed to the 
observed decrease in cellular NAD
+
 levels during differentiation. Follow-up analysis of 
expression level of other enzymes utilizing NAD
+
 is warranted to explain this 
observation. In this context, it is interesting to mention the recent report of Frederick 
and colleagues demonstrating that increasing NAD
+
 biosynthesis in the skeletal muscle 
is not alone sufficient to increase metabolic function (Frederick et al., 2015). 
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It should also be noted that while downregulated in myotubes compared to myoblasts, 
PARP-1 is not completely absent in the differentiated myotubes. For instance, 800 μM 
H2O2 induces 70% depletion of NAD
+ 
content in undifferentiated cells but only 30% 
depletion in differentiated cells (Figure 22C). Accordingly, oxidative stress does have 
some effect on these cells - though relatively minor when compared to myoblasts - that 
is reduced by inhibition of PARP-1. Also, in vivo, there is a constant turnover of the 
muscle, meaning that skeletal muscle probably represents a mixed population of cells in 
various stages of differentiation and correspondingly, various degrees of PARP-1 
expression and oxidative stress resistance. These notions are consistent with a recent 
report by Pirinen and colleagues (Pirinen et al., 2014) that demonstrated that treating 
mice with pharmacological inhibitors of PARP-1 exerted beneficial effects on skeletal 
muscle endurance and performance, coupled with increased cellular NAD
+
 content, 
mitochondrial function, and mitochondrial biogenesis. 
 
5. 2. The localization of PARP-1 during oxidative challenge and the 
effect of propranolol on the PARP-1 activation in U937 and C2C12 
cells 
 
We found that an early and specific activation of PARP1 occurs in the mitochondria in 
oxidatively stressed U937 cells. The functional consequences of such activation is 
modulated by the β-adrenoceptor antagonist propranolol suggesting a cAMP/PKA and 
PARP-1 interplay. 
The findings are noted here might serve as a cellular base for the advantageous outcome 
in propranolol treated patients discussed below.  
 
5. 3. Poly(ADP-ribosyl)ation in skeletal muscle tissue of pediatric 
patients with burn injury: the positive effect of propranolol 
 
Severe burn injury induces pathophysiological response affecting the whole body 
including muscle, lung, heart and liver. Studies in rodent and large animal models of 
burn injury have demonstrated the activation in various tissues and the beneficial effect 
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of its pharmacological inhibition (Bartha et al, 2011; Asmussen et al., 2011). In a 
murine model of severe burn injury in heart and lung tissue exhibited increased PARP-1 
activity and more pronounced mitochondrial DNA damage than their non-injured 
counterpart, which clearly demonstrates the critical role of PARP-1 in thermal injury 
(Szczesny et al., 2015).  As a primary study to map the role of PARP-1 in critical illness 
such as burn injury, we measured the PARP-1 activation in human skeletal muscle 
biopsies at various stages of severe pediatric burn injury. In conjunction with that, we 
tested the effect of propranolol, an effective treatment for burn patients, on the PARP-1 
activation in skeletal muscle biopsies. We found that PARP-1 became activated in 
skeletal muscle tissue 13-18 days after burn and localized primarily to vascular 
endothelial cells and resident mononuclear cells to some degree. There was a marked 
suppression of PARP activation in the skeletal muscle biopsies of patients who received 
propranolol treatment. Our conclusion was that some of the clinical benefits of 
propranolol in burns might be related to its inhibitory effect on PARP activation (Olah 
et al., 2011). Aforementioned results from our lab demonstrated that inhibiting PARP-1 
has a beneficial outcome on the systemic effect of burn in patient.  
Other studies have shown the profitable effect of exercise on muscle of burn patients: 
for instance, improved lean body mass, peak torque, muscle strength endurance (Hardee 
et al., 2014; Porter et al., 2015a; Porter et al., 2015b). This could partially be explained 
by the elevated effectiveness of the antioxidant apparatus and/or mitochondrial 
respiratory capacity. If we assume that two cohorts of burn patients, exercised and non-
exercised, have the same PARP level/response but different antioxidant capacities, it 
can be concluded that in the exercised group the more effective antioxidant capacity 
serves to neutralize PARP-1 overactivation thus improving physical function in severely 
burned patients. 
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6. Future directions 
 
Observations made in the current study that remain to be investigated include (a) the 
functional consequence of the variable regulation of various 'minor' PARP isoforms 
during differentiation (i.e. downregulation of PARP-2 and PARP-7 and upregulation of 
PARP-3), (b) the mechanism through which glycolytic activity increases after PARP-1 
silencing in myoblasts, and (c) the reasons why the downregulation of PARP-1 during 
differentiation is cell-type dependent. It is interesting to note that inhibition of PARP-2 
has recently been shown to produce an increase in mitochondrial biogenesis in skeletal 
muscle (Mohamed et al., 2014). (d) For burn patients it would be also beneficial to 
explore if incorporating antioxidants or PARP inhibitors as a supplement to exercise 
program currently used enhances the outcome of therapy. Along with the exercise 
program in severely burned patient, it would be useful to incorporate antioxidant or/and 
PARP-inhibition supplementation as a treatment for a more robust positive outcome and 
investigate muscle function such as lean body mass, peak torque, muscle strength 
endurance parallel with the identification the molecular triggers of PARP activation in 
burn patients to better address the therapy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
86 
7. Conclusions 
 
Based on multiple lines of functional data, we concluded that the functional importance 
of the differentiation associated decrease in PARP-1 in C2C12 muscle cells is that it 
endows myotubes with increased oxidative stress resistance and bioenergetic function. 
We realize that the regulation of PARP-1 in myoblasts and myotubes may be a 
specialized case since PARP-1 has multiple roles in a variety of cell types ranging from 
promotion of survival in cancer cells to actively mediating necrosis in parenchymal 
cells and catalyzing pro-inflammatory gene expression in immune cells (Jagtap and 
Szabo 2005; Pacher and Szabo 2008; De Vos et al., 2012). Changes in PARP-1 
expression may well have very different roles depending on the cell type and the 
(patho)physiological context. 
We showed an early PARP-1 activation in a mitochondrial localization and the 
inhibition of PARylation by the β-adrenoceptor agonist propranolol. 
 We also provided evidence for PARP activation in muscle tissue of burn patients and 
were able to demonstrate the protective effect of propranolol. In order to clarify the 
exact mechanistic role of PARP in human burns, future, interventional studies with 
PARP inhibitors would be necessary. 
 
 PARP-1 protein expression level is markedly decreased during skeletal muscle cell 
differentiation in murine and rat cell-based models 
 The reduced level of PARP-1 in myotubes results greater oxidative stress resistance 
than their undifferentiated counterparts. 
 PARP-1 participates in the regulation of muscle cell bioenergetics under normal 
conditions and during oxidative challenge. We showed increased respiratory parameters 
in myoblasts with siRNA-mediated silencing of PARP-1 suggesting a beneficial effect 
of the depletion. 
 There is an early-onset of PARP-1 activation in the mitochondria in U937 cells and can 
be inhibited by the β-adrenoceptor agonist propranolol. 
 Pharmacological inhibition of PARP-1 has a beneficial effect in burn patients. 
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8. Summary 
 
Poly(ADP-ribose) polymerase 1 (PARP-1), the major isoform of the poly (ADP-ribose) 
polymerase family, is a nuclear and mitochondrial protein with well-recognized roles in 
various essential cellular functions such as DNA repair, signal transduction, apoptosis, 
as well as in a variety of pathophysiological conditions including burn, sepsis, diabetes 
and cancer. Activation of PARP-1 in response to oxidative stress catalyzes the covalent 
attachment of the poly (ADP-ribose) (PAR) groups on itself and other acceptor proteins, 
utilizing NAD
+
 as a substrate. Overactivation of PARP-1 depletes intracellular NAD
+
 
influencing mitochondrial electron transport, cellular ATP generation and, if persistent, 
can result in necrotic cell death. Skeletal muscle cells are particularly exposed to 
constant oxidative stress insults during exercise. In this study, we investigated the role 
of PARP-1 in a well-defined model of murine skeletal muscle differentiation (C2C12) 
and compare the responses to oxidative stress of undifferentiated myoblasts and 
differentiated myotubes. We observed a marked reduction of PARP-1 expression as 
myoblasts differentiated into myotubes. This alteration correlated with an increased 
resistance to oxidative stress of the myotubes, as measured by MTT and LDH assays. 
Mitochondrial function, assessed by measuring mitochondrial membrane potential, was 
preserved under oxidative stress in myotubes compared to myoblasts. Moreover, basal 
respiration, ATP synthesis, and the maximal respiratory capacity of mitochondria were 
higher in myotubes than in myoblasts. Inhibition of the catalytic activity of PARP-1 by 
PJ34 (a phenanthridinone PARP inhibitor) exerted greater protective effects in 
undifferentiated myoblasts than in differentiated myotubes. The above observations in 
C2C12 cells were also confirmed in a rat-derived skeletal muscle cell line (L6). Forced 
overexpression of PARP1 in C2C12 myotubes sensitized the cells to oxidant-induced 
injury. We also showed that oxidative stress, such as H2O2 treatment (for 10minutes), 
caused an early-onset of PARP-1 activation in the mitochondria assessed by PLA 
analysis and at later time point (at 3-24 hours) the activation occured in the nucleus.  
We compared PARP activation in normal skeletal muscles and muscles from different 
time point after burn injury ('Early', 'Middle' and 'Late' groups) and found that the 
PARylation mainly affected PARP-1 at ~120kDa, although other proteins were also 
modified by the PARylation process. The other goal of the study was to evaluate the 
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effect of propranolol therapy on the PARP activation. The main finding was the reduced 
PARylation in the 'Middle' and in some degree in the 'Late' group compared to the 
patients who did not receive propranolol. In order to study the mechanism of the 
protective effect of propranolol, we showed that the β-adrenoceptor signaling is inolved 
in the PARP-1 activation in U937 and C2C12 cells since propranolol inhibited the 
PARylation in both cells after H2O2 challenge. 
Taken together, we showed that (a) the reduction of PARP-1 during differentiation 
serves as a protective mechanism against oxidative stress. (b) PARP-1 activation during 
oxidative challange occurs in the early time points in the mitochondria and hours later 
in the nucleus. (c) this PARP-1 activation can be inhibited by the β-adrenoceptor 
agonist propranolol which (d) has beneficial effect in burn patients. 
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9. Összefoglalás 
 
PARP-1, poli(ADP-ribóz) polimeráz 1 a PARP család egyik fő izoformája, ez a család 
emberben 17, egérben 16 fehérjéből áll. Egy folyamatosan termelődő sejtmagi és 
mitokondriális fehérje jól ismert szereppel különböző sejtes funkciókban, mint például 
DNS (dezoxiribonukleinsav) hibajavításban, jelátviteli folyamatokban, különböző 
sejtahalál útvonalakban es különböző kóros folyamatokban mint égés, szepszis, 
cukorbetegség es rák. A PARP által szabályozott legtöbb funkció oxidatív stresszhez 
kapcsolt. A PARP-1 aktivációja oxidatív stimulus hatására poli(ADP-ribóz) egységek 
kovalens kapcsolását jelenti egyrészt saját magára az enzimre, illetve célfehérjékre 
NAD
+
 felhasználása mellett. A PARP-1 "túlaktivácioja" NAD+  szint csökkenéshez 
vezet, amely befolyásolja a mitokondriális elektron transzportot és amennyiben 
továbbra is fennáll, nekrotikus sejthalálhoz vezet. Harántcsíkolt izomszövet testedzés 
folyamán folymatos oxidattív stimulus alatt áll. Vizsgálataink során kimutattuk a 
PARP-1 szerepét izomdifferenciáció során és összehasonlítottuk az oxidatív stressz 
hatását differenciálatlan és differenciált C2C12 egér sejtekben. Megfigyeltük, hogy 
differenciáció alatt a PARP-1 fehérje szintje csökkent, amely emelkedett oxidatív 
stressz rezisztenciával járt együtt a differenciált sejtekben amit LDH es MTT mérésével 
igazoltunk. Miotubulusok mitokondriális membrán potenciálja oxidatív körülmények 
között megtartott volt a nem differenciált sejtekhez képest, emelkedett bazális 
respiráció, ATP szintézis és maximális respirációs kapacitás mellett. A PARP-1 
inhibitor PJ34 védő hatást mutatott a differencciált mioblasztokban oxidáns kezelésre, 
míg a miotubulusokban ez a hatás nem volt megfigyelhető. Ezeket a megfigyeléseket 
egy másik sejtvonalban, L6 patkány izomsejtben is kimutattuk. PARP-1 
overexpressziója a C2C12 miotubulusokban oxidánssal szembeni érzékenység 
növekedésével járt. H2O2  kezelés hatására egy korai fazisú (10 perc) mitokondriális, 
illetve egy késői fázisú (3-24 óra) sejtmagi PARP-1 aktivációt regisztrátunk PMA 
analízissel. Egy összehasonlító elemzést is elvégeztünk normál és az égés után 
különböző időpontban vett izom biopszia mintákból, amelyből azt a következtetést 
vontuk le, hogy a PARP-1 aktiváció leginkább a középső csoportot ("middle") érintette 
összehasonlítva a kontrol csoporttal. A PARiláció elsősorban magát a PARP-1 enzimet 
érintette 120 kDa-nál, de más fehérjék is érintettek voltak. A tanulmány fő célja az volt, 
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hogy megállapítsuk vajon rendelkezik-e védő hatással a propranolol. Kezelés hatására a 
PARiláció csökkent volt a középső ("middle") és bizonyos fokig a késői ("late") 
csoportban összehasonlítva a kezeletlen csoporttal. Annak érdekében, hogy 
megállapítsuk a propranolol hatásának mehanizmusát illetve a folyamat kapcsolatát a β-
adrenoceptor jelátvitellel, U937 és C2C12 sejteket kezeltünk H2O2-dal és 
megállapitottuk, hogy a propranolol gátolta a PARilaciós folyamatot. 
Eredményeinket összefoglalva megállapíthatjuk, hogy (a) a PARP-1 fehérje szintjének a 
csökkenése egy védő hatást jelent a differenciált miotubulusoknak oxidatív stresszel 
szemben. (b) PARP-1 aktiváció oxidatív stimulus hatására egy korai, percekben 
mérhető, mitokondriális és egy késői, órákkal később lezajlódó, nukleáris, fázisokra 
bonthatóak. (c) Ez a PARP-1 aktiváció gátolható β-adrenoceptor agonista propranolollal 
amelynek (d) kedvező hatása van égett betegekben. 
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